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ABSTRACT
Magnetic nanoparticles (MNPs) are currently being extensively studied in
multitude of biomedical applications because of their exceptional biocompatibility. By
attaching different targeting ligands/molecules, MNPs have been broadly used in
magnetic hyperthermia, cancer therapy, targeted drug delivery, MRI imaging, pathogen
detection, and biological cell-separation. In this dissertation, MNPs coated with
polyethylene oxide (PEO) based polymer (PEO-MNPs) and functionalized with bacterial
adhesin-specific glycoconjugate molecule Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp (GM3MNPs), are investigated for their interactions with enterotoxigenic Escherichia coli (E.
coli). It also describes the feasibility of using alternating magnetic fields (AMF) for
targeted killing of E. coli K99 (EC K99) strain using MNPs. Lastly, the interactions of
MNPs with normal human colon cells CCD-18Co are explored to assess their in vitro
biocompatibility.
First, GM3-MNPs were synthesized via 'click chemistry' platform. Specific
aggregation of EC K99 was seen due to interactions occurring between GM3-MNPs and
adhesin molecules of EC K99. These interactions were observed by means of
fluorescence microscopy, transmission electron microscopy (TEM), and colony forming
units (CFU) assays. The preliminary cytotoxicity assay performed on normal colon cells
CCD-18Co

indicated

excellent

biocompatibility

of

GM3-MNPs.

Thus,

such

glycoconjugate-functionalized MNPs can be effectively utilized as anti-adhesion and
anti-bacterial agents for reducing gastro-intestinal (GI) tract infections.
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Next, GM3-MNPs were used along with AMF for targeted killing of EC K99
cells. CFU/ml assays indicated that killing rate of EC K99 was mainly dependent on
concentration of GM3-MNPs and AMF exposure time. Clinically relevant reduction in
CFU/ml of EC K99 was achieved after 120 minutes of AMF exposure in presence of
GM3-MNPs in both pure and mixed bacterial culture environment. Extensive cellmembrane damage was observed via fluorescence microscopy and TEM imaging of EC
K99 cells after AMF exposure in presence of GM3-MNPs. AMF exposure in presence of
GM3-MNPs also caused significant decrease in intracellular ATP levels of EC K99.
These results suggest that bacterial specific glycoconjugate MNPs along with AMF can
be efficiently employed as novel non-antibiotic platform to inactivate targeted bacterial
pathogens.
Finally, the overall biocompatibility of GM3-MNPs was examined in CCD-18Co
cells and compared to that of PEO-MNPs. GM3-MNPs were found to have relatively
stable hydrodynamic diameter in cell-culture media DMEM whereas PEO-MNPs
drastically increased their size on account of protein-corona formation. Both cytotoxicity
and ATP assays revealed that GM3-MNPs exhibited great biocompatibility in the cells.
CCD-18Co cells also maintained their overall cell-membrane integrity in the presence of
GM3-MNPs. Interestingly, GM3-MNPs were able to substantially decrease the
glutathione (GSH) levels in the cells leading to increased oxidative stress. Thus, by
properly controlling surface properties of glycoconjugate functionalized MNPs and
attaching different drugs, they can be potentially used as colon specific drug-delivery
carriers for therapeutic applications.
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Chapter 1
Literature Review
Antibiotic Resistance in Bacteria
Currently, there are more than 160 different kinds on antibiotics available for
therapeutic purposes [1]. However, unrestricted and prolonged usage of antibiotics has
resulted in rapid emergence of new strains of microorganisms that have developed
resistance to these drugs and over a period of time they have evolved as multi-drug
resistant microorganisms. For example, the first penicillin-resistant strain of
Streptococcus pneumoniae was observed in USA in 1974 in a patient suffering from
pneumococcal meningitis [2]. Methicillin resistant Staphylococcus aureus (MRSA) and
vancomycin resistant Enterococci (VRE) were first identified in the 1960s [3] and in the
mid-1980s [4] respectively. Some of the mechanisms commonly found in these
antibiotic-resistant pathogens are alteration of drug target, degradation of drugs by
producing enzymes, changes in target accessibility and increased drug efflux [5] (Figure
1.1). According to a recent report by CDC, approximately 2 million people in the US
have illnesses related to antibiotic resistant infections and each year at least 23,000 deaths
occur as a result of such infections [6]. Given the fact that developing new antibiotics is a
slow and costly affair, there is an urgent need to treat such infections by employing
therapies that do not require the traditional usage of antibiotics [7-9].
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Figure 1.1 Different mechanisms employed by bacteria to render antibiotic useless. Reprinted from [5] - Reproduced
with permission from Nature Publishing Group.

Role of Adhesin in Bacterial Attachment and Pathogenesis
Pathogen attachment is a very complex phenomenon and a vital process to initiate
infection in the host-cell. The microorganisms have to initially colonize themselves onto
the host-cell surfaces and grow in sufficient numbers in short span of time to produce
clinical symptoms [10, 11]. Bacterial pathogens typically target animal or human host by
attaching onto epithelial and mucosal surfaces of respiratory tract, gastrointestinal tract
and genitourinary tract [12]. Bacterial adhesion is essential since pathogens have to
overcome different nonspecific defense mechanisms like sneezing and fluid flow
occurring in the host. Adhesion also enables the pathogen to utilize host-cell nutrients in
order to multiply rapidly along with enabling the pathogen to deliver toxin in the host-cell
and ultimately penetrating into the host tissue [13].
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Bacterial pathogens utilize two primary mechanisms to adhere onto host cells,
namely carbohydrate-protein recognition and protein-protein interaction [14]. Most of the
studies to understand adhesion mechanisms are done by linking carbohydrate-protein
recognition process since it is very difficult to elucidate the protein-protein interaction on
account of protein instability and its changing conformations [15]. The carbohydrateprotein interaction that binds bacterial pathogens onto the host-cell tissue are mediated by
specialized structures called adhesin/fimbriae, which have lectin proteins and are located
on the microbial surface. Fimbriae are typically expressed by almost every gram-negative
bacterial species that has been studied [16]. It should be however noted that bacterial
adhesion mediated by fimbriae is a highly specific phenomenon. The adhesion structures
have a high degree of preference for a particular host-cell tissue. For example, E. coli
usually colonizes GI tract whereas Streptococci colonize the skin and esophagus in
humans [17]. Several comparative studies have been done to address the species
specificity of bacterial adhesins for a particular type of host-cell receptor [14].

Biological Importance of Carbohydrates in Pathogenesis
It was only in the early 1990s that carbohydrates were recognized as important
biomolecules, which had great diversity, and thereby carbohydrate molecules were
explored for finding their applications in medical and pharmaceutical industries [18].
Apart from their roles in cell metabolism, carbohydrates play an important role in various
biological processes like inflammation [19], cancer metastasis [20] and cell-signaling to
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name a few. They also play modulatory role in hormone signaling and typically act as
receptor molecules for attachment of antibodies, proteins and other biomolecules [19].
Adherence of pathogens onto host-cell is one of earlier events that can trigger the onset of
infection. The binding affinity of a single carbohydrate-protein interaction is generally
weak on account of monovalency. However, multiple interactions between the
carbohydrate molecule and its respective protein result in polyvalency, which greatly
enhances the binding capacity and thereby aids in the adherence process [21, 22]. By
taking advantage of these multiple adherence factors, a large number of bacteria, their
toxins, and viruses are able to gain entry into the host-cell and exert their harmful effects
on the host-cell.
The adhesion process of bacteria attaching onto the host-cell is complex in nature.
This attachment is mediated by bacterial lectins that are present on their surface. These
lectins, generally in the form of fimbriae, recognize specific glycolipid or glycoprotein
receptors present on the host-cell surface [23]. E. coli is one such enteropathogen that
expresses different types of pili e.g., Type-1 pili, P-type fimbriae, S-type fimbriae, etc.
Table 1.1 gives us more information regarding the receptor specificity of these bacterial
fimbriae.
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Table 1.1: Receptor specificity of bacterial fimbriae. Modified from [24]. Reproduced with permission from Elsevier
Ltd.

Apart from bacterial pathogens, their toxins and even viruses have been shown to
bind to specific carbohydrate molecules. The viral protein hemagglutinin has been shown
to bind to host-cell N-Acetylneuraminic acid and this interaction has been found to be
polyvalent in nature [22]. Similarly, other viruses like rotavirus and Sendai virus have
been found to attach to specific carbohydrate ligands [22]. Clinically important bacterial
pathogens like enterotoxigenic E. coli, Vibrio cholera, Shigella dysenteriae all produces
lethal toxins which are responsible for causing diseases ranging from mild diarrhea to
lethal toxic shock induced death in humans. These toxins are able to exert their toxic
effects by entering the host-cell after binding to their carbohydrate receptors. It has been
found that cholera toxin and heat-labile enterotoxin attach themselves onto the luminal
side of the intestinal epithelium by binding to GM1 gangliosides [25]. The Shiga-like
toxins have been found to bind onto the host-cell receptors through Gb3 ceramide
glycolipids [26, 27].
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Enterotoxigenic Escherichia coli
E. coli is one of the most common types of bacteria naturally occurring in the
digestive tract of humans and animals. While most of the E. coli strains are harmless to
humans and animals, there are few E. coli serogroups that are mainly responsible in
causing bacterial infection. These strains typically tend to be host-specific. The
prevalence of the serogroups and presence of adhesins are considered to be the primary
factors that facilitate intestinal colonization of E. coli. Based on different serological
features, enteric E. coli have been classified into 5 different groups: 1) Enterotoxigenic E.
coli (ETEC), 2) Enteropathogenic E. coli (EPEC), 3) Enteroinvasive E. coli (EIEC), 4)
Enterohemorrhagic E. coli (EHEC), and 5) Enteroaggregative E. coli (EAEC) [28]. The
production of different types of toxins by these serovar groups is considered to play very
crucial role in producing clinical signs of infection. E. coli belonging to the ETEC group
is responsible for causing traveler’s diarrhea in humans and bloody diarrhea in neonatal
calves, pigs and lambs [29]. Though enough reports have cemented the importance of
adhesins in the overall process of infection caused by E. coli in humans, few studies have
been conducted to understand the pathogenesis of ETEC strains in farm animals. ETEC
adhere to small intestinal microvilli membranes in vivo via adhesins and produce
enterotoxins that act on enterocytes and thereby causing diarrhea [30]. Recently,
numerous studies have reported an increase in multi-drug resistance of this strain
associated with antibiotic treated animal feed [31-34]. E. coli K99 is the main causative
agent of bloody diarrhea in young calves, lambs and pigs, a condition also known as
colibacillosis [35]. The disease typically affects newborn animals within 2-3 weeks of
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birth. This strain bears K99 antigen which also acts as fimbriae and adheres the bacterium
onto the ileal villus epithelium of calf and pigs [36-39]. E. coli K99 strain specifically
attaches to small intestinal mucus and recognizes sialic acid derivatives present on
glycolipid receptors [40]. Experimental studies have shown that glycoprotein glycans
isolated from bovine plasma inhibited the fimbriae specific adherence of E. coli K99 to
mucus glycoproteins [41]. Oral administration of these glycans protected young calves
from the infection and reduced the number of bacteria present in small intestine mucus by
100 folds. This showed that such glycans could effectively act as anti-adhesive
molecules, which can prevent colibacillosis in young farm animals.

Role of Carbohydrates in Anti-adhesion Therapy
It was not until 1990s that the concept of using carbohydrates as natural antiadhesive agents came into limelight. The need for finding new strategies in order to
combat the growing concern of antibiotic-resistant strains of microorganisms, aided the
research in glycol-biology field with special focus in microbiological context. Several
studies were carried out in this aspect and showed the feasibility of carbohydrates as an
alternative to conventional antibiotic treatment [42-44]. The concept of using
carbohydrates as new anti-adhesion agents is mainly based upon the following
hypotheses: 1) Microbial infection is initiated due to binding of the pathogen onto the
host-cell and 2) Anti-adhesive agents must either interfere with the binding of pathogen
to the host or help in detachment of microbes from the host tissues during early stages of
infection [13, 45]. Since these anti-adhesive agents interfere with adhesin-host-cell
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receptor (proteins) interactions, it would be much easier to develop analogues that
interact with carbohydrate receptors as it is difficult to elucidate the exact protein
structure [44].
Numerous natural carbohydrates and synthetic glycoconjugates have been used to
understand this mechanism of anti-adhesion in bacteria and viruses [43, 46, 47]. Since
synthetic glycoconjugates typically have low binding affinity, they can be used as
polymers, dendrimers and liposomes in order to attain multivalency and achieve effective
high affinity and inhibitory effect against various carbohydrate receptors and this has
been shown in both in vitro and in vivo studies [48, 49].

Role of Carbohydrate Functionalized Nanomaterials in Pathogen
Detection
Rapid, sensitive and reliable methods for detection of microorganisms hold the
key for accurate diagnosis of infectious diseases. Conventional techniques commonly
used for this purpose include culture and colony counting, polymerase chain reaction and
immunological assays [50-53]. However, these approaches are laborious, timeconsuming and having low sensitivity thresh-hold levels. Moreover, you encounter
numerous false-negative results by using the above-mentioned conventional methods. It
is in this context that the use of nanomaterials has provided a great impetus for rapid and
accurate detection of microbial pathogens in food and clinical samples. These
nanomaterials can act as unique nano-biosensor for specific detection of complex
biologically relevant molecules like proteins, nucleic acids and enzymes [54]. It is now

8

possible to specifically detect microorganisms by functionalizing nanoparticles with
specific antibodies and ligands. Since carbohydrate molecules are actively involved in
host-cell recognition process leading to pathogenicity, coating the nanomaterials with
such glycan molecules can provide a unique platform in rapid detection of pathogens
including bacteria, virus and parasites. The underlying principle in this approach depends
on the fact that providing multiple copies of different glycan molecules on the surface of
nanomaterials would mimic the glycan present on the outer envelope of pathogen or the
cell glycocalyx itself. Several studies have been carried out in this regard by exploiting
the unique optical and magnetic properties of gold nanomaterials and magnetic
nanomaterials respectively for rapid and specific detection of pathogens [55-65]. The
adhesin-specific functionalized magnetic nanoparticles that we will be using in this
research, can potentially find their application as unique nano-biosensor for rapid
pathogen detection.
Lin et al. were one of the first few groups who used mannose functionalized thiolcoated gold nanoparticles as novel and sensitive agents for detecting E. coli cells in
biological fluids proving the usefulness of carbohydrate functionalized nanoparticles in
studying carbohydrate-protein adhesion [66]. They observed bacterial strain-specific
aggregation of mannose functionalized gold nanoparticles via TEM imaging and UV-Vis
spectroscopy. E. coli ORN 178 strain, which has FimH gene and type 1 pili showed
specificity towards mannose functionalized gold nanoparticles whereas E. coli ORN 208
strain, which lacked FimH gene and type 1 pili did not bind to nanoparticles.
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Carbohydrate functionalized nanoparticles were also employed to rapidly detect bacterial
toxins

in

biological

solutions.

Schofield

and

co-workers

synthesized

gold

glyconanoparticles coated with lactose for colorimetric detection of cholera toxin (B
subunit) [63]. They noticed a rapid change in the color of the gold nanoparticle solution
when cholera toxin B was added to it and this was attributed to the shift in surface
plasmon band of the nanoparticle solution, which takes place due to aggregation of these
nanoparticles in presence of the toxin. Similarly, another study was undertaken by
Kulkarni et al. in which they synthesized biocompatible glycan conjugated gold
nanoparticles for selective inhibition of shiga toxin 1 and 2 in Vero monkey kidney cellline [64]. Their nanoparticles were functionalized with analogues of Pk trisaccharide
molecules, which can mimic the glycolipid glycans present on the cell-surface receptors
to which the toxin can attach. The results obtained by this work suggested a dosedependent inhibition of Stx toxin in Vero cells.

Role of Carbohydrate Functionalized Nanomaterials in Anti-Adhesion
Antimicrobial Therapy
Advances in the fields of nanomaterials synthesis and synthetic glycoconjugate
production have seen a rapid increase since early 2000. As new technologies are being
developed, it has become relatively easy to custom synthesize different carbohydrate
molecules/glycan conjugates and use them to bio-functionalize nanoparticles that can be
then utilized in anti-adhesion therapies. Some of the most commonly employed
nanomaterials in anti-adhesion therapies are gold nanoparticles, carbon nanotubes and
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magnetic nanoparticles [67, 68]. To be effectively used as anti-adhesion agents, the
carbohydrate molecules needs to have multivalent interactions with the host-cell surface
receptors. For bacterial pathogens to initiate infection, they must be able to bind to host
cell-surface receptors. These binding interactions are either carbohydrate-protein or
carbohydrate-carbohydrate interactions in nature. Thus, in order to interrupt/inhibit these
interactions, carbohydrate analog molecules that mimic the cell-surface receptors are
frequently coated on the surface of nanoparticles thereby acting as novel anti-adhesion
antimicrobial agents. Some of the early research studies carried out in these fields
included gold and magnetic nanoparticles functionalized with mannose or galactose
derivatives.
For example, Huang et al. used silica-coated magnetic nanoparticles
functionalized with mannose for rapid detection and separation of E. coli from medium
[69]. After incubating mannose coated magnetic nanoparticles with bacterial cells, they
applied external magnetic field to rapidly isolate the bacterial cells and their capture
efficiency was ~88%. When these captured E. coli cells were observed under
fluorescence microscopy and TEM imaging, they found large aggregates of
nanoparticles-bacterial cells complex. These complex structures were attributed to lectincarbohydrate interactions taking place between adhesin molecules of E. coli and mannose
molecules present on the surface of magnetic nanoparticles. Similar studies were carried
out by Qu et al. wherein they functionalized the surface of polymeric nanoparticles with
multiple copies of mannose/galactose and found out that E. coli 178 cells would
agglutinate only in presence of mannose functionalized nanoparticles whereas E. coli
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O157:H7 cells would aggregate only in the presence of galactose functionalized
polymeric nanoparticles [60, 70]. Few other studies also showed anti-adhesion properties
of carbohydrate-functionalized nanoparticles in mammalian cells as well as in turkey
poults infected with Helicobacter pylori and Campylobacter jejuni respectively [68, 71].

Magnetic Nanoparticles
Synthesis of magnetic nanoparticles: The synthetic approach to manufacture
magnetic nanoparticles plays a very important role in determining the size, shape and its
magnetic properties. Some of the main advantages of using superparamagnetic
nanoparticles in the biological environment are increased surface area, improved
diffusion rates in body fluids and tissues and high colloidal stability [72]. Commonly
used approaches for synthesizing magnetic nanoparticles are co-precipitation, thermal
decomposition,

sol-gel

synthesis,

micro-emulsion,

ligand-exchange

reaction,

hydrothermal and high-temperature reactions, polyol methods, spray pyrolysis, and
aerosol/vapor methods [73]. Nonetheless, the common aim of all the above-mentioned
synthesis methods is to achieve a highly stable and monodisperse nanoparticle suspension
with suitable size requirements. Moreover, it has been noticed that the size and shape of
the nanoparticle is also dependent on the temperature, reaction time-period and
concentration of the reagents. Keeping in view that these nanoparticles would interact
with different biomolecules once they enter biological environment, it is imperative to
make sure that the synthesized nanoparticles are highly nontoxic and in most of the cases,
this depends on the method of nanoparticle synthesis [74]. Recently, nanoparticle
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synthesis through high-temperature thermal decomposition technique has been
efficaciously used in producing iron-oxide nanocrystals with enhanced controls in size
distribution, shape and monodispersity with high degree of biocompatibility [75].
Stabilization of magnetic nanoparticles with polymers: Uncoated magnetic
nanoparticles tend to aggregate rapidly at neutral pH and in various biological
environments. This aggregation takes place because of the strong dipole attractions in
form of Van der Waals forces, occurring between the particles. To overcome this
problem, stearic or electrostatic repulsion must be achieved which would then stabilize
the nanoscale colloidal suspension. Addition of different polymers onto the core of
magnetic nanoparticles would render high stability in biologically aqueous environments.
The stabilizing agents can be briefly categorized into 3 classes’ namely 1) monomeric
stabilizers which includes various functional groups like carboxylates, phosphates, and
sulfates, 2) inorganic stabilizers which includes gold, silver, and silica, and 3) polymer
stabilizers which are the most commonly used materials for stabilizing core magnetic
nanoparticles [74].
Some of the most commonly used polymer coatings for stabilizing core magnetic
nanoparticle are dextran, starch, alginate, chitosan, polyethylene glycol (PEG) or
polyethylene oxide (PEO), polyvinyl alcohol (PVA), polyethylene oxide (PEO),
polyacrylic acid (PAA), and polyethylene amine (PEI) to name a few. Most of these
polymers are reported to have good biocompatibility properties and thereby are
extensively used in biomedical applications [76]. It has been also noticed that the
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molecular weight and surface charge of these polymers play crucial role in determining
the stability of nanoparticle suspension in biological environments [72, 74, 77, 78].
PEG can be broadly classified into 2 categories depending on the type of terminal end
group: 1) Monofunctional PEG - which has same functional group on both its ends and 2)
Heterobifunctional PEG - which has 2 different reactive groups on each ends. Some of
the most commonly used end terminal groups for PEGylation are acid chlorides,
carbonates, aldehydes, amides, amine, carboxylic acids, NHS esters, etc. [78-81].
Some of the early studies involving usage of PEO for biomedical applications were
carried out in 1970s. Abuchowski et al., for the first time, showed covalent attachment of
PEG molecule (PEGylation) to bovine live enzyme, catalase [82]. They observed that
attachment of PEG significantly increased the blood circulation time of these enzymes
without triggering any immune response in mice. Since PEG is a known biocompatible
polymer having no known cross-reaction with water molecules, it has been used
extensively for drug delivery applications. Covalently attaching drug/protein molecules to
PEG can increase its water solubility and overall hydrodynamic size. This actually helps
in prolonged circulatory time as the increase in size diameter reduces its renal clearance
rate. Some of advantages of attaching PEOs onto nanoparticles are that they are highly
stable, biocompatible and approved by FDA, amphiphilic in nature, soluble in water as
well as in many other solvents, can act as carrier molecule in different pharmaceutical
products and the ease of manipulating its surface chemistry for wide-spread use in
different biomedical applications [72, 83-87].
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Magnetic Properties
Generally, almost all materials are magnetic in nature to a certain level. When
exposed to external magnetic field (H), they display varying amount of small magnetism.
Accordingly, they can be classified as either 1) paramagnetic or 2) diamagnetic materials.
Also, there are few materials that exhibit higher ordered magnetic states even in the
absence of externally applied magnetic field. Such materials have been distinctly
classified into 3 categories namely ferromagnetic, ferrimagnetic and antiferromagnetic
materials. This classification has been based on the magnetic susceptibility of the
magnetic materials.
In paramagnetic materials, the magnetic moments are aligned parallel to H and
they tend to retain their magnetic properties even when the external magnetic field is
removed. In the case of diamagnetic materials, their magnetic properties are lost as soon
as external field is removed. It should be noted that both para- and dia-magnetic materials
have no collective magnetic interactions and their magnetic domains are not ordered. In
ferri- and ferro-magnetic materials, the magnetic moments are also aligned parallel to H,
however, there is a subtle difference in the coupling interactions that take place between
the electrons of the magnetic material. The antiferromagnetic materials have the magnetic
moments that are aligned anti-parallel to H. One of the unique features of all of the above
3 materials is that they exhibit highly ordered state magnetic domains and large
spontaneous magnetization [88].
When the size of the nanoparticle goes below a certain value (~20 nm), then each
individual nanoparticle can behave as a single magnetic domain that exhibits
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superparamagnetic properties. When external magnetic field is applied, the magnetic
dipoles to such nanoparticles will reorient and in the absence of magnetic field, the net
magnetic moment will be zero. In contrast to paramagnetic materials, in
superparamagnetic materials, the electrons spin alignment occurs in a single domain
nanoparticle and not in a single atom. This is the reason as to why superparamagnetic
nanoparticles respond very quickly in presence of external magnetic field [88]. When
such nanoparticles are effectively stabilized with polymer coatings, they find myriad
applications in the medical field.

Use of Magnetic Nanoparticles in Magnetic Hyperthermia for
Therapeutic Applications
Hyperthermia is a type of treatment therapy wherein there is a drastic temperature
increase in the body tissues. Hyperthermia therapy has been used for treating cancer since
1957 [89]. Typically, heat treatment by means of hyperthermia can be classified into 3
categories: mild temperature hyperthermia (37⁰C to 42⁰C), moderate hyperthermia (43⁰C
to 46⁰C) and thermal ablation (>46⁰C). Moderate hyperthermia is clinically approved
treatment option for cancer therapy. Some of the cellular processes, which are directly
affected by hyperthermia, are protein degradation, heat stress, and induction of apoptosis
in cancer cells [90]. In the last decade, several studies have established the potential of
using nanomaterials in cancer therapy and disease management. Various biomolecules
like DNA, RNA, peptides, mRNA, and antibodies have been used as targeting ligands to
specifically deliver the nanomaterials to cancer cell/tissue. Among the different kinds of
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nanomaterials used in cancer treatment, magnetic nanoparticles have been extensively
studied because of their biocompatibility and multi-functionality. When magnetic
nanoparticles are exposed to alternate magnetic fields, they generate heat and increase the
temperature of the surrounding environment (conversion of magnetic energy into heat
energy). This application is known as magnetic hyperthermia and it has been successfully
employed in treating different kinds of cancers in vitro and in vivo [91]. This heat
generation occurs because of Neel and Brown relaxation and hysteresis losses [92, 93]
(Figure 1.2). The heat generation efficiency of MNPs in presence of AMF is measured in
terms of specific absorption rate (SAR). The higher the SAR value, the better is the heat
producing capacity of MNPs. It has been reported that SAR value is influenced by
number of factors like nanoparticle size and its surface chemistry, its shape and applied
frequency and field intensity of AMF [72]. Also, SAR value is dependent upon the
exposure time of AMF and the solvent in which MNPs are suspended.
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Figure 1.2 Schematic representation showing possible mechanisms of conversion of magnetic energy into heat energy.
Reprinted from [89] - Reproduced with permission from Elsevier Ltd. and IEEE.

Magnetic hyperthermia therapy using magnetic nanoparticles has been clinically
used for treating tumors along with traditional chemotherapy and radiation therapy [9496]. Moreover, several studies have also attached a targeting molecule (e.g., antibody,
protein molecule, anti-cancer drug) for cancer cells specific therapy using MNPs. In
majority of these studies, due to presence of targeting molecule on the surface, the
nanoparticles are able to attach and enter only in cancer specific cells. This has been
found to be extremely advantageous as once the nanoparticles are attached to the cancer
cells, applying alternate magnetic fields will heat up only the cancer specific cells/tissue
leaving the non-cancer cells/tissue harmless [72, 90, 97-102] (Figure 1.3).
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Figure 1.3 Magnetic nanomaterials based hyperthermia therapy applications. Reprinted from [89] - Reproduced with
permission from Elsevier Ltd.

Such targeted magnetic hyperthermia treatment can potentially revolutionize
cancer therapy regimen by drastically reducing the side effects, which are usually found
with chemotherapy. The heating rate of MNPs in magnetic hyperthermia is found to be
dependent on numerous factors like concentration of nanoparticles, nanoparticle core size
and shape of nanoparticles, surface chemistry of nanoparticles, applied frequency and
field intensity of the instrument, and time [90]. Moreover, magnetic nanoparticles have
also been successfully used as commercial contrasting agents in MRI imaging [91].
However, there are very few reports of treating bacterial infections by using magnetic
hyperthermia [103-105].
One such study performed by Thomas et al. used magnetic hyperthermia in
presence of carboxylic-acid functionalized MNPs as alternative treatment option for
killing Staphylococcus aureus cells [106]. They exposed the bacterial cells to AC
magnetic field in presence of relatively high concentration of MNPs (up to 50 mg/ml).
107-log reduction in bacterial counts was observed within 4 minutes of magnetic
hyperthermia treatment in presence of 50 mg/ml concentration of MNPs. In another
similar work, Park and co-workers studied the inactivation rate of Pseudomonas
aeruginosa biofilms in presence of commercially available superparamagnetic iron oxide
nanoparticles (SPIONs) and AC magnetic fields [104]. ~4-log reduction in biofilm was
achieved through 8 minutes of magnetic hyperthermia treatment using concentration of
60 mg/ml MNPs. They attributed this reduction to disintegration of bacterial cell
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membrane at elevated temperatures, which are attained during the hyperthermia
treatment. It should be duly noted that in both the above mentioned research studies, the
killing of bacterial cells was mainly achieved by sheer increase in the bulk temperature
through high concentrations of MNPs and AC magnetic fields. Also, none of the above
studies utilized any specific targeting molecule/ligand for targeted hyperthermia therapy.

Magnetically Mediated Energy Delivery (MagMED)
According to conventional theories, applying external alternate magnetic fields in
presence of MNPs would result in macroscopic temperature rise and hence aptly referred
to as magnetic hyperthermia therapy. The main drawback of this therapy is that to
actually get a clinically relevant temperature increase in the living systems mainly in
vitro and in vivo models, large concentrations of MNPs is needed. As majority of the ongoing clinical studies utilizing magnetic hyperthermia therapy through MNPs is for
cancer treatment, it is not feasible to directly deliver such a large payload of nanoparticles
to the desired location in the body via commonly administered routes, e.g., intravenous,
intranasal, transdermal, intrathecal, etc. which could substantially increase the
temperature of the body region/tissue.
One possible way to reduce the concentration of MNPs to get desired results in
terms of killing cancer cells or tumors is to actually make MNPs in such a way that they
can be completely internalized by these cells and can target the intracellular pathways
providing selective killing without actually rising the overall temperature of the system.
In such cases, it would be incorrect to use the term magnetic hyperthermia. Hence, a few
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research groups (Dr. Carlos Rinaldi, University of Florida; Dr. O. Thompson Mefford,
Clemson University) coined the term ‘magnetically mediated energy delivery’
(MagMED) to explain the instances where apoptosis of cancer cells was achieved in
presence of MNPs and alternate magnetic fields without a major change in the overall
temperature of the system [100].
Recent experimental studies have shed new insights on explaining how local
temperature rise is attained during MagMED treatment without bulk temperature
increases in tissue environment. A study by Huang et al. showed that it is possible to
remotely activate calcium ion channels in neural cells through alternate magnetic fields
with minimal changes in bulk temperature of the tissues [107]. They synthesized
manganese ferrite nanoparticles functionalized with streptavidin, which can selectively
bind to TRPV1 receptors in neural cells. Finally, they grafted thermal responsive
fluorophores on the outer surface of nanoparticles and used alternate magnetic fields to
thermally activate ion channels. Through this study, the authors were able to show ~20°C
increase in local temperature on the surface of nanoparticles without bulk temperature
rise based on the changes in the fluorescence intensity of the fluorophores that were
present on the nanoparticles surface.
In another study, Creixell and co-workers performed MagMED experiments in
which they observed 99.9% reduction in viability of breast cancer cells in presence of
iron-oxide

nanoparticles

[108].

They

functionalized

dextran-coated

iron-oxide

nanoparticles with epidermal growth factor (EGF) targeting ligands that can
preferentially attach only to cancer cells. After MagMED therapy, they noticed that the
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targeted nanoparticles were greatly internalized by the breast cancer cells compared to
non-targeted ones and resulted in reduction in cell-viability of those cells. During this
study, they did not notice any measurable increase in temperature when AMF was
applied. An extension of the above study by the same research group tried to elucidate the
underlying mechanism by which MNPs present in intracellular regions can prove toxic to
cancer cells in presence of AMF without bulk temperature increase [109]. The same
targeted group of nanoparticles were mixed with breast cancer cells and in presence of
AMF, the internalized MNPs could selectively induce lysosomal membrane
permeabilization of breast cancer cells. The authors suggested that increased lysosomal
permeabilization could result in cellular death of breast cancer cells through increase in
reactive oxygen species (ROS) and lysosomal cathepsins production in presence of AMF.
In all of the above reported MagMED studies, the exact mechanisms of
intracellular events that are responsible for apoptosis of cancer cells in presence of AMF
and MNPs are still not fully understood. Some of the possible ways through which these
events are currently explained are: 1) highly localized increase of temperature on the
surface of nanoparticles can disrupt several signaling pathways in cells; 2) application of
AMF in presence of MNPs can physically/mechanically damage the cell membrane via
Neel and Brownian relaxation processes (rotational or vibrational moments of
nanoparticles).
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Biocompatibility of Magnetic Nanoparticles
In last two decades, there has been tremendous increase in the usage of
engineered nanomaterials for various industrial products and the demand is rapidly
increasing. Analysts have forecasted that nanomaterial based industrial products will
drive the global economic markets by more than 100 billion dollars per annum between
the years 2011-2015 [110]. The flexibility to engineer different types of nanomaterials
with desired physico-chemical properties has made it possible to use these nanomaterials
in numerous biomedical applications. In fact, nanomaterials based treatment therapies for
cancer diagnosis and therapy, drug delivery and imaging are already in clinical trial
stages [111-117]. However, several factors regarding biocompatibility and toxicity of
these nanomaterials still need to be addressed in detail. There is a complex relationship
between the morphology, size and chemical properties of these nanomaterials that would
eventually determine its toxicity in living organisms and the environment [110, 118-120].
The magnetic properties displayed by magnetic nanoparticles have been extensively
utilized in wide range of biomedical applications like MRI imaging, drug delivery,
pathogen detection, magnetic cell-separation or magnetic hyperthermia [80, 121-123].
Magnetic nanoparticles have also increased the overall efficacy of anticancer drugs and
its presence has also reversed multidrug resistance commonly found in cancer cells [124].
To render magnetic nanoparticles biocompatible, they need to be coated with suitable
polymers, which would keep them stable in biological environment. Depending on the
overall size of the nanoparticle system, the stabilizing polymer and the type of chemical
group present on the polymer end, MNPs can behave and interact differently with the
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proteins present in the biological environment. Although magnetic nanoparticles have
been reported to have excellent biocompatibility [125-127], they might exert toxicity to
the host cell depending on their size, surface chemistry and its ability to interact with the
proteins present in body fluids. Numerous in vitro and in vivo studies have demonstrated
differential toxicity of MNPs [78, 79, 124, 128-131]. The different toxicity mechanisms
observed in determining safe dosage levels of MNPs in these studies include impaired
mitochondrial function, cytotoxicity, cell apoptosis, DNA damage and genotoxicity,
immunotoxicity, oxidative stress, disordered cell morphology, cytoskeleton damage, cellmembrane damage etc. [131-136]. Therefore, an in-depth and thorough analysis of
toxicological profile of MNPs are warranted to make sure that they are biocompatible in
living systems before using them clinical settings.

Objectives
MNPs bio-functionalized with different polymers and molecules have been
researched widely for diverse biomedical applications. The kind of targeted moiety
attached onto surface of MNPs determines the kind of interactions it would have with
bacterial and mammalian cells. These interactions are greatly dependent on kind of
synthesis procedures used for making MNPs, size of MNPs, type of polymer used as
stabilizing agent and finally on the type of cell with which MNPs interacts both in in vitro
and in vivo conditions. The main goal of this dissertation was to synthesize proof-ofconcept bacterial adhesin specific MNPs that are bio-functionalized with specific
glycoconjugate molecule (GM3), and which can selectively interact with EC K99 strain
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in absence/presence of AMF. The first aim deals with synthesizing mono-anchored GM3MNPs that are stabilized with heterobifunctional PEO polymer and evaluating its
interactions with EC K99. The second aim explores the feasibility of using multianchored GM3-MNPs in conjunction with AMF for targeted killing of EC K99 both in
pure and mixed culture environment and trying to explain the possible mechanisms
through which EC K99 is destroyed. And the last aim investigates the biocompatibility
and interaction of our novel MNPs system with normal human colon cells CCD-18Co by
employing various toxicity assays. The results obtained in this project will greatly help in
providing a unique non-antibiotic platform for treating bacterial infections via MNPs and
AMF with minimum toxicity to host-tissue.
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Chapter 2
Synthesis and Application of Glycoconjugate-Functionalized Magnetic
Nanoparticles as Potent Anti-adhesion Agents for Reducing
Enterotoxigenic Escherichia coli Infections
[This chapter is taken directly or adapted from work published in Nanoscale journal by
Raval et al. (2015); DOI: 10.1039/c5nr00511f. Copyrights 2015 - Reproduced by
permission of The Royal Society of Chemistry. Website link:
http://pubs.rsc.org/en/Content/ArticleLanding/2015/NR/C5NR00511F#!divAbstract]

1. Introduction:
There has been a recent uprising in the emergence of new multi-drug resistant
bacterial strains in the environment, which has resulted in increased morbidity and
mortality throughout the world [1-3]. As a result, alternative therapeutic options that are
non-antibiotic based are urgently needed to treat such bacterial infections. There have
been considerable ongoing scientific interests in understanding multivalent carbohydratelectin interactions for various purposes like receptor mimicking, inhibiting bacterial
growth and as novel anti-adhesion agents for treating bacterial infections [4-8].
Functionalizing multivalent carbohydrate molecules onto the surface of different
nanomaterials offers numerous advantages, e.g., higher affinity constants (Ka) and
enthalpy of binding (ΔH) [9, 10], than their monovalent forms in studying ligand-receptor
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interactions [11]. Nonetheless, there have been limited reports of using such
carbohydrate-functionalized nanomaterials as specific anti-bacterial and anti-adhesion
agents. Due to high surface/volume ratio of nanoparticles, it is relatively easy to attach
various carbohydrate moieties onto their surface, which has found useful applications in
rapid pathogen/toxin detection and its inhibition [12-14]. In several studies, gold
nanoparticles [15], magnetic nanoparticles [16], carbon nanotubes [17, 18], polymeric
nanoparticles [19-21], and diamond nanoparticles [22] were bio-functionalized with
various carbohydrate sugars and used as mimicking agents of host-cell surface receptors
that selectively interacted with the adhesin molecules of various E. coli strains and
resulted in rapid agglutination [20] and reduction in colony forming units (CFUs) of these
E. coli strains [21]. The unique magnetic properties and biocompatibility displayed by
magnetic nanoparticles have been extensively utilized in wide range of biomedical
applications like MRI imaging [23], pathogen detection [24], drug-delivery [25], and
magnetic hyperthermia [26]. Keeping MNPs stable in biological environments is
important in their biomedical applications. Numerous polymer anchor groups like amines
[27], alcohols [28], phosphates [29], and carboxylic acids [30] have been utilized to
render colloidal stability to MNPs in highly protein-rich biological environments. Of late,
anchor groups based on catechols have been extensively researched to provide stable
platform for synthesizing multifunctional MNPs [31-34].
Bacterial pathogens utilize two primary mechanisms to adhere onto the host-cell
namely carbohydrate-protein recognition and protein-protein interaction [35]. Bacterial
adhesin molecules, which take part in carbohydrate-protein interaction, bind bacterial
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pathogens onto the host-cell tissue through specific glycolipid or glycoprotein receptors
[36]. Enterotoxigenic Escherichia coli (ETEC) infection is one of the most common
cause of traveler’s diarrhea in humans and also in neonatal farm animals like calves, pigs
and lambs [37]. Recently, numerous studies have reported increases in multi-drug
resistance of ETEC associated with antibiotic treated animal feed [38-41]. Majority of the
fimbrial adhesins isolated from ETEC that infected farm animals expressed one or more
unique adhesins. These adhesins also act as antigens/virulence factors [41]. EC K99 is the
main causative agent of bloody diarrhea in young calves, lambs and pigs, a condition also
known as colibacillosis. This strain bears K99 antigens, which also act as fimbriae
facilitating the adherence of EC K99 onto the ileal villus epithelium of calf and pigs and
help in initiation of infection [42, 43]. The adhesins of EC K99 specifically attach to
small intestinal mucus and recognize sialic acid derivatives present on glycolipid
receptors [4, 44]. Hence, if this attachment is disrupted, then there is high probability of
preventing bacterial infection.
The use of bacterial adhesin-specific glycoconjugate functionalized nanoparticles
for prevention/treatment of infections offers several advantages in that it can be designed
to target only a specific strain or a specific group of pathogens; it does not impose
selection pressure on bacteria exposed to it, hence, minimizing the emergence of resistant
bacteria; it is more stable and less expensive than antibodies-based targeting systems, etc.
In our previous lab research, we have demonstrated that gold nanoparticles biofunctionalized with specific sialic-acid sequences can cause rapid aggregation of EC K99
[45]. Here, we extend our work and further study the intricate details of glycoconjugate
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receptor binding specificity of this sequence molecule (Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp)
coated on MNPs (GM3-MNPs) towards EC K99 by employing various microscopic
techniques and bioassays and show that these MNPs can effectively act as novel nontoxic anti-adhesion agents in reducing ETEC infections.

2. Experimental Section:
Synthesis of Heterobifunctional Polyethylene Oxide (alkyne-PEO-nitroDOPA):
The chemical synthesis of heterobifunctional polyethylene oxide polymer having alkyne
at one end and nitroDOPA on the other end is schematically shown in figure 2.1. This
complex polymer was synthesized by Roland Stone (PhD student in Dr. O. Thompson
Mefford’s group, Clemson University). More details regarding the intricate experimental
steps involved in synthesizing this polymer and its characterization can be found in the
publication, Stone et al. 2014 [46].
Synthesis of Magnetic Nanoparticles: The 7.2nm magnetic nanoparticles,
synthesized using thermal decomposition of iron(III) acetylacetonate (2mmol), 1,2hexadecanediol (10mmol), olylamine (4mmol), benzyl ether (20ml), and 6nm iron oxide
seeds were added and stirred under a nitrogen flow and brought to 200°C for 1hr to get
rid of any moisture. Finally the reaction was brought to reflux for 30mins under a
nitrogen head. The particles were purified by precipitation of ethanol and characterized
using TEM and DLS.
Modification of Magnetic Nanoparticles: The magnetic nanoparticles were
modified by first dissolving alkyne-PEO-nitroDOPA (200 mg, 0.04mmol) into 10ml of
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chloroform followed by the slow addition of 1ml (2mg/ml) of magnetic nanoparticles,
which were also dispersed in chloroform, while sonicating over 30 mins. The solution
was allowed to stir overnight. The particles were then purified by precipitation with
hexane, centrifuged to separate particles from solvent. They were then dispersed in
ethanol and subsequently precipitated using hexane and separated via centrifugation to
collect particles. Finally, the particles were dispersed in deionized water and dialyzed for
3 days.
Synthesis

of

Magnetic

Nanoparticles

Functionalized

with

GM3

Glycoconjugate: The particles with an alkyne surface were then modified using ‘click
chemistry’ with glycoconjugate (Neu5Ac(α2-3)-Gal(β1-4)Glcβ-sp) and azide, 1 : 4
respectively using a copper catalyst for 24 hours in the absence of light. The particles
were then dialyzed for 3 days to remove any unbound glycoconjugate, catalyst, and any
byproducts of the reaction.
Dynamic Light Scattering (DLS) and Zeta-Potential: DLS was performed on the
PEO-coated and GM3-coated magnetic nanoparticles to determine their hydrodynamic
radius. The nanoparticle suspensions were diluted in water and placed into a cuvette.
Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to determine the
intensity average size distribution and z-average diameter. Zeta-potential measurements
of these nanoparticle suspensions were also determined using the same instrument. The
suspensions were diluted with water and added into zeta-cell and three measurements
were taken at 25°C.
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Inductively Coupled Plasma Mass Spectroscopy (ICP-MS): The nanoparticle
concentration in PEO-MNPs and GM3-MNPs was determined by performing ICP-MS
(Thermo-Scientific MS XSeries 2). The nanoparticle suspensions were treated with 2%
nitric acid solution in a 15 ml centrifuge tube and subsequently measurements were
taken.
Fourier

Transform

Infrared

Spectroscopy

(FTIR):

FTIR

assisted

microscopy was done using a Thermo-Nicolet Magna 550 FTIR spectrometer equipped
with a Thermo-NicPlan FTIR microscope. Scan number was 16 for each sample
including background. Background was collected on a clean germanium plate. Samples
were prepped by taking the water suspensions/solution and casting a small drop on a
germanium plate. The samples were then set under a heat lamp for 10-15 minutes to dry,
resulting in a thin film from which spectrum could be collected using an FTIR
microscope.
Fluorescence Microscopy Aggregation Assay: Both EC K99 (ATCC 13762)
and non-virulent strain E. coli O157:H7 6980-2 (EC 6980-2; control strain) were
transformed

with

plasmids

pGREEN

and

pGFPuv

respectively

by

electroporation[47]. The green-fluorescent protein (GFP) expressing E. coli strains
were grown in tryptic soy broth/tryptic soy agar (TSB/TSA) supplemented with
ampicillin (100 µg/ml). Freshly grown E. coli cultures were used for aggregation
assays. After growth, the bacterial cells were centrifuged thrice and re-suspended
in 1X sterile phosphate buffered saline (PBS). Approximately, 5 x 107 CFU of
bacterial cells were prepared based on optical density (OD600) readings. PEO-
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MNPs (40 µg/ml) and GM3-MNPs (40 µg/ml) were mixed with both EC K99 and
EC 6980-2 and this mixture was incubated at room temperature for 30 minutes
with gentle shaking. Based on previous method [21], fluorescence microscopy
assays were performed at the end of incubation time to visualize nanoparticlesmediated bacterial aggregation.
TEM Imaging of GM3-MNPs and EC K99: TEM imaging was performed to
evaluate the specific binding interactions between GM3-MNPs and EC K99. GM3-MNPs
were added to EC K99 (5 x 107 CFU/ml, suspended in 1X PBS) in an eppendorf tube for
30 minutes at room temperature with gentle shaking. The mixture was centrifuged at
7000 x g for 5 minutes to spin down the bacterial cells along with adherent GM3-MNPs.
The supernatant containing unbound GM3-MNPs was removed and the pellet was
washed thrice with 1X PBS in repeated centrifugation cycles. This mixture was then
fixed in cacodylate-buffered glutaraldehyde (3.5%, pH ~7.4) for 10 -12 hours at 4°C.
Subsequently, 3 µl of this mixture was dropped onto a carbon-coated copper grid and
allowed to air-dry for 30 minutes. Later, the grids were stained with 2% uranyl acetate
solution (3 µl) for 5 minutes and blotted dry with filter-paper (Whatman #4). TEM
images were taken on Hitachi H7600 at 120 kV power and magnification ranging from
10000X to 100000X.
CFU Aggregation Assay: In order to determine the extent of GM3-MNPs
induced bacterial aggregation, a CFU reduction assay was carried out as previously
described [21]. Briefly, both the E. coli strains were standardized to a
concentration of 5 x 107 CFU in 1X PBS. These bacterial suspensions were then
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mixed with different amounts of PEO-MNPs and GM3-MNPs (40 µg/ml and 100
µg/ml) and the mixture was allowed to incubate at room temperature for 30
minutes with gentle shaking. Serial dilutions of these mixtures were made and 50
µl of sample from each dilution tube was transferred onto a sterile, empty petri
plate in triplicates. Then, 20 ml of molten TSA (maintained at 45°C) supplemented
with ampicillin (100 µg/ml) was carefully poured into the petri plates. The plates
were gently rotated to ensure proper mixing of sample and TSA. Finally, after the
TSA in the plates solidified, the plates were incubated at 37°C overnight. Next
day, the colonies on the plates were counted and CFU reduction was compared to
control plates.
ATP Assay: To confirm that the reduction in CFU of EC K99 was achieved only
due to GM3-MNPs induced bacterial aggregation and not because of inherent toxicity of
these nanoparticles, an ATP determination assay [48] was performed using BacTiterGlo™ microbial cell viability kit (Promega, Madison, WI) following manufacturer’s
protocol.
Cytotoxicity Assay: To further validate the non-toxic nature of our nanoparticles
system, we performed a preliminary cytotoxicity assay on human colon (normal) cell-line
CCD-18Co and determined its cell-viability rate after exposing to GM3-MNPs for 24
hours. CCD-18Co Human colon cells (normal) were procured from American Type
Culture Collection (ATCC) and grown on 50 cm2 tissue-culture flask (Corning, NY) in
the presence of Eagle’s Minimum Essential Medium (EMEM) at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. EMEM was supplemented with 2 mM L-Glutamine,
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non-essential amino acids, fetal bovine serum (final concentration – 10%), 100 UI/ml
penicillin G, and 100 µg/ml streptomycin. For determining the cytotoxicity of GM3MNPs, cells between passage generation of 12 and 20 were used. 1.5 x 104 cells/well
were seeded (in triplicates) in 96-well culture-plates at 37°C in a humidified atmosphere
of 5% CO2 and 95% air. After 24 hours, varying concentration of GM3-MNPs were
added to the cells and incubated for further 24 hours. Next day, MTS assay (CellTiter 96®
Aqueous One Solution Cell Proliferation Assay, Promega, USA) was performed
according to manufacturer’s protocol and the plate was read at 490 nm optical density to
measure the absorbance of the formazan product using a microplate reader (Thermo
Scientific Multiskan™ FC).

3. Results and Discussion:
In this chapter, we report the synthesis of MNPs coated with heterobifunctional
polyethylene oxide (PEO-MNPs) having nitroDOPA as a stable anchoring agent and biofunctionalized with sialic-acid glycoconjugate (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp) (GM3MNPs) via ‘click chemistry’(Figure 2.1). These GM3-MNPs can effectively act as
multivalent ligands, which specifically interact with adhesins present on the EC K99.
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Figure 2.1 Synthesis of heterobifunctional polyethylene oxide coated magnetic nanoparticles bio-functionalized with
sialic-acid derivative (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp).

A heterobifunctional polyethylene oxide (PEO), with a molecular weight of 6300
g/mol, with a protected alcohol on one end and an alcohol on the other was synthesized
by the anionic polymerization of ethylene oxide (EO) using tetrahydropyranol as an
initiator. The alcohol end group was then modified with an alkyne via a substitution
reaction using propargyl bromide (1:4 respectively). Once modified, the protected alcohol
group was deprotected with an acid and subsequently purified. Finally, using Nhydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide (DCC) coupling, the
heterobifunctional PEO was modified with nitrated 3,4 dihydroxy-L-phenylanaline
(nitroDOPA) to yield a macromolecule with functionality that can be utilized for ‘click
chemistry’ and provide enhanced binding to an iron oxide surface, as described in
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previous work by Stone et al.[46], where synthetic details the polymer formation and
relevant NMR data can be found. NitroDOPA was selected as the binding group for our
system because of its enhanced binding to metal oxides [49].
The aforementioned macromolecule was then used to modify MNPs, synthesized
using a modified version of a procedure by Sun et al.,[50] via ligand-exchange by slowly
adding magnetic nanoparticles dispersed in hexanes to a solution of the macromolecule in
chloroform while sonicating. After 12 hours, allowing for significant ligand exchange,
the polymer-particle complex was then purified by extraction into DI water and then
dialyzed against DI water in 12-14,000 g mol-1 MWCO dialysis membranes for three
days to remove any impurities. The use of nitroDOPA containing PEO polymer has
recently been shown to be the most effective anchoring chemistry in the ligand exchange
of oleic acid coated particles [51]. The resulted particles with attached glycoconjugate
(GM3-MNPs) were characterized by dynamic light scattering (DLS) (Table 2.1), zetapotential (Table 2.1) and FT-IR spectroscopy (Figure 2.2 and 2.3). The absence of azide
peak at 2113 cm-1 in Figure 2.2 (D) represents the successful conjugation of
glycoconjugate moiety onto the polymer-coated magnetic nanoparticles through
cycloaddition. The nanoparticle concentration in PEO-MNPs and GM3-MNPs was
determined by means of inductively coupled plasma mass spectroscopy (ICP-MS).
Type of MNPs

DLS (Z – Avg) (d. nm)

Zeta-Potential

PEO-MNPs
GM3-MNPs

77.31
80.46

-12.1
-42.0

Table 2.1 DLS and Zeta-Potential measurements of MNPs after functionalizing PEO polymer and GM3 molecule.
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Figure 2.2 FTIR of DOPA (Top) and NitroDOPA (Bottom). Symmetric and asymmetric stretching from the NO2 peaks
at 1330 and 1532 cm-1. Reprinted from (46) - Reproduced by permission of The Royal Society of Chemistry.

Figure 2.3 FTIR spectroscopy of A.) Magnetite particles modified with the alkyne PEO stabilizer, B.) The Neu5Ac(α23)Gal(β1-4)Glcβ-sp targeting moiety prior to “clicking”, C.) The resulting complex of magnetic nanoparticles with the
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Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp moiety, and D.) The resulting spectrum of subtracting spectrum C by A indicating the
successful conjugation of the Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp to targeting molecule.

Clearly, large aggregates of EC K99 were observed in the presence of GM3MNPs (Figure 2.4). No visible aggregation was found when EC K99 was mixed with
PEO-MNPs (Figure 2.4 c). Moreover, EC 6980-2 did not form aggregates when mixed
with PEO-MNPs and GM3-MNPs (Figures 2.4 a and b). This shows that both E. coli
strains clearly have different sugar binding specificities and that EC K99 exhibits binding
specificity only to GM3-MNPs.

Figure 2.4 Fluorescent microscopy images of EC 6980-2 and EC K99 in presence of PEO-MNPs and GM3MNPs. (a) and (b) EC 6980-2, in the presence of PEO-MNPs and GM3-MNPs respectively; (c) and (d) EC
K99, in the presence of PEO-MNPs and GM3-MNPs respectively. Magnification – 400X and scale bar – 100
µm.
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Furthermore, transmission electron microscopy (TEM) analysis of the mixture
containing GM3-MNPs and EC K99 was done to observe intricate details of bacterial
aggregation. The samples for TEM analysis were prepared according to a modified multistep protocol [21, 52]. Large clusters of bacterial cells were observed due to strong
interactions between GM3-MNPs and EC K99 (Figure 2.5 a and b). The GM3-MNPs
were found covering the entire surface of EC K99. Because of significant binding of
multiple GM3-MNPs onto individual bacterial cells and other GM3-MNPs acting as
linking agents to interact with other bacterial cells, we observed significantly large
agglutination of EC K99.

Figure 2.5 TEM images of GM3-MNPs induced bacterial aggregation of EC K99. Magnification of (a) and (b) are
30000X and 60000X, respectively. Scale bar is 500 nm.

Entero-pathogenic E. coli strains have different sugar binding affinities depending
on the type of adhesins present on their outer cell-surface [53]. It is known that EC K99
has S type of fimbrial proteins that specifically recognizes and binds only to Neu5Ac(α23)Gal(β1-4)Glcβ-sp sialic-acid sequences [4]. The pilus of EC K99 is primarily made up
of FanC, major fimbrial sub-unit gene product, which is responsible for recognizing and
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attaching the bacterium to the sialic-acid ganglioside receptors present on the host-cell
[54]. On the other hand, EC 6980-2 have adhesin molecules that consist of galactosebinding proteins on its outer surface which can attach to galactose receptors [17] present
on the host-cell and hence EC 6980-2 was not able to form bacterial aggregates when
mixed with GM3-MNPs. Based on these sugar-binding specificities, the above mentioned
2 different E. coli strains were selected for this study.
As shown in figure 2.6 A, approximately 2-log reduction in CFU of EC K99
was observed in the presence of GM3-MNPs (40 µg/ml). This reduction was due to
GM3-MNPs induced bacterial aggregation. Also, 1-log reduction of EC K99 was
observed at 100 µg/ml concentration of GM3-MNPs. Interestingly, there was no
reduction in CFU of EC 6980-2 in the presence of either GM3-MNPs or PEO-MNPs
(Figure 2.6 B). These results correlate with those obtained in fluorescence microscopy
assay showing that bacterial cells of EC K99 aggregating in clusters of several 100s of
bacterial cells in the presence of GM3-MNPs. Surprisingly, EC K99 in the presence of
GM3-MNPs (100 µg/ml) resulted only in 1-log reduction in CFU since the nanoparticlebacteria ratio was different. Luo and co-workers [21] obtained similar results when they
incubated E. coli ORN178 in the presence of different concentrations of mannosefunctionalized polymeric nanoparticles. Thus, it is imperative to attain appropriate
nanoparticle-bacteria ratio for getting maximum reduction in CFU mediated by
nanoparticles-induced bacterial aggregation.
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Figure 2.6 (a) CFU/ml assay of EC K99 in the presence of different concentrations of GM3-MNPs and PEO-MNPs
and (b) CFU/ml assay of EC 6980-2 in the presence of different concentrations of GM3-MNPs and PEO-MNPs. Data
expressed as Mean ± SD (n = 3); Statistical Analysis – Two-Way Analysis of Variance (ANOVA) (*** - P<0.0001).

Intracellular ATP levels of both the E. coli strains were recorded by
measuring their relative luminescence in the presence/absence of GM3-MNPs (40 µg/ml)
and PEO-MNPs (40 µg/ml). Figures 2.7 A and B shows that there is no significant
difference in intracellular ATP levels of both E. coli strains in the presence of
nanoparticles. Also, another important feature to determine the toxicity of nanoparticles
is to look for any cell-membrane damage and morphological changes in the bacterial cellmembrane structure [52]. Results of TEM imaging of EC K99 in the presence of GM3MNPs showed no visible bacterial cell-membrane damage suggesting the non-toxic
nature of our nanoparticles. These results suggest that the reduction in CFU of EC K99
was achieved only because of GM3-MNPs induced bacterial aggregation and not due to
nanoparticle toxicity.
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Figure 2.7 Intracellular ATP Assay (a) Relative Luminescent Units (RLU) of EC K99 when incubated with GM3MNPs and PEO-MNPs (b) RLU of EC 6980-2 when incubated with GM3-MNPs and PEO-MNPs. Data expressed as
Mean ± SD (n = 3); Statistical Analysis – One-Way Analysis of Variance (ANOVA); (P>0.05).

To further validate the non-toxic nature of our nanoparticles system, we
performed a preliminary cytotoxicity assay on human colon (normal) cell-line CCD-18Co
and determined its cell-viability rate after exposing to GM3-MNPs for 24 hours. The
potential cytotoxicity of GM3-MNPs was measured by performing MTS assay. As seen
in figure 2.8, there was no significant reduction in cell-viability rate of CCD-18Co cells
in the presence of varying concentrations of GM3-MNPs. These results suggest that our
novel glycoconjugate-functionalized nanoparticle system is highly biocompatible.
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Figure 2.8 Cytotoxicity assay to determine cell-viability of CCD-18Co cells in presence of different concentrations of
GM3-MNPs. Data expressed as Mean ± SD (n = 3); Statistical Analysis – One-Way Analysis of Variance (ANOVA);
(P>0.05).

4. Conclusion:
In conclusion, we successfully synthesized heterobifunctional polymer coated
magnetic nanoparticles that have nitroDOPA as a stable anchoring agent and were biofunctionalized with sialic-acid glycoconjugate (Neu5Ac(α2-3)Gal(β1-4)Glcβ-sp) (GM3MNPs) using click chemistry. The GM3-MNPs were characterized by employing
different techniques and their adhesin specificity was determined using aggregation
assays. Our GM3-MNPs specifically interacted only with ETEC strain EC K99 as
confirmed through fluorescence microscopy and transmission electron microscopy. Also,
a 2-log reduction in CFU of EC K99 was achieved due to GM3-MNPs induced bacterial
aggregation. Moreover, intracellular ATP assays demonstrated that the 2-log reduction in
CFU of EC K99 was not due to inherent toxicity of the nanoparticles. Thus, our proof-ofconcept nanoparticle system can effectively serve as novel non-antibiotic multivalent
carriers, which could find applications in detection and capturing of pathogenic multi-
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drug resistant bacterial strains from active physiological body fluids. Our systems can
especially reduce/treat gastro-intestinal tract infections caused by ETEC pathogens in
farm animals and humans since specific bacterial-nanoparticle aggregates can be
effectively flushed out from the body system because of high peristaltic flows without
disturbing the normal gut microflora that is usually destroyed when antibiotics are used.
This system can also be employed as potent anti-adhesion agents that can block/inhibit
specific cellular responses by competitively preventing the attachment of bacterial
pathogens onto specific eukaryotic cell-surface receptors and thereby reducing the
infection load. Furthermore, this nanoparticle system can also be utilized for targeted
magnetic hyperthermia treatment of bacterial infections, especially those that are resistant
to multiple antibiotics. In future work, nanoparticles with multi-anchored functional
groups will be utilized to improve stability of nanoparticles in biological fluids and to
enhance their bindings to specific pathogens. Their therapeutic values, i.e., selective
killing of pathogens via hyperthermia mediated by glycoconjugate-functionalized
magnetic nanoparticles, will be evaluated both in vitro in cell-line and in vivo in small
animal systems. In addition, potential toxicities associated with the use of these
nanoparticles will be characterized using various biological assays, e.g., cytotoxicity,
genotoxicity, immunogenicity assays, etc.
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Chapter 3
Multi-Anchored Glycoconjugate-Functionalized Magnetic
Nanoparticles: A Tool for Selective Killing of Targeted Bacteria via
Alternating Magnetic Fields
[This chapter is taken directly or adapted from work published in Advanced Functional
Materials journal by Raval et al. (2017); DOI: 10.1002/adfm.201701473. Copyrights
2017 - Reproduced by permission of John Wiley and Sons. Website link:
http://onlinelibrary.wiley.com/wol1/doi/10.1002/adfm.201701473/abstract]

1. Introduction:
The emergence of anti-microbial resistance (AMR) has quickly taken hold as one
of the greatest threats to modern medicine on a global scale, and the ramifications, if not
dealt with in a timely manner, may be catastrophic. Currently, there are more than 160
different kinds of antibiotics available for therapeutic purposes [1]. However, unrestricted
and prolonged usage of antibiotics has resulted in rapid emergence of new strains of
bacteria that have developed resistance to these drugs and, over time, evolved as multidrug resistant microorganisms. Infections caused by such bacterial strains have resulted
in prolonged hospital stays and an increase in outpatient costs and patient mortality and
morbidity throughout the world [2]. In a World Health Organization (WHO) global report
on antimicrobial resistance, it is stated that AMR is a complex global public health
challenge and that no single or simple strategy will contain the emergence and spread of
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AMR infectious organisms [3]. A recent study by the US Center for Disease Control and
Prevention estimates that every year, diseases caused by AMR strains of bacteria infect
millions of people in the US, and thousands of them die annually due to lack of new
antibiotics [4]. The emergence of AMR also has an enormous socio-economic impact. A
2014 report from RAND Europe, estimates the economic cost of AMR to be
approximately 3.1% of global output gross domestic product (~2.4 trillion US dollars)
[5]. Although recognized as an immediate issue, antibiotic discovery has declined with
many major pharmaceutical companies discontinuing their antibiotic development
programs over the past decade due to low return on investment and difficulties in
identifying new compounds. This reinforces the need for development of novel
therapeutic approaches to address the AMR challenges [6-8].
Nanoparticles have been a highly investigated area as their properties differ from
their bulk counterparts. Of these materials, iron oxide has found particular prevalence in
the biomedical field with use in MRI contrast, drug delivery, cell separation, and cancer
therapy [9-11]. When an iron oxide particle is subjected to an alternating magnetic field,
a hysteresis loop is completed in which the area relates to the energy release per cycle
[12]. By doing this at relatively high frequencies (kHz-MHz), the amount of energy
transfer is great enough to affect surrounding cells [13]. This phenomenon was
previously referred to as magnetic hyperthermia due to an observed temperature rise.
However, recent studies have shown that cell death could be induced in the absence of
bulk heating of the environment [13, 14]. In seeking a more descriptive term, we and
others prefer to use the phrase magnetically mediated energy delivery (MagMED) [15,
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16]. The use of nanoparticles for biological applications requires stringent attention to
surface chemistry as it affects reactivity, bio-distribution, and stability [9, 17]. Much
research has been put into optimizing surface chemistries for nanomaterials, with
poly(ethylene oxide) (PEO) being one of the universally accepted coatings [18]. PEO has
been shown to prolong circulation time, greatly improve stability in protein and ion-rich
environments, impart secondary functionality, and render stealth from the immune
system [18]. Further enhancement in stability may be imparted using a multi-anchored
catechol as the iron binding moiety [17, 19]. This is highly necessary as desorption of the
polymer coating is an issue with many biomolecules including phosphonates and
peptides, which have high affinity for iron oxide [20].
Though numerous groups have reported using alternate magnetic field along with
magnetic nanoparticles as an alternative cancer therapy, limited work has been done in
the same direction for treating bacterial infections [21-23]. More importantly, to the best
of the authors’ knowledge, no work exploring the use of nanoparticles for selective
killing of targeted pathogen in mixed-bacterial culture settings has been reported.
Attachment of bacterial pathogens onto the surface of mammalian cells is one of the
foremost events in host-pathogen interactions. Several pathogenic bacteria are able to
adhere to specific host-cell receptors via carbohydrate binding proteins, also called
adhesins or lectins [24]. These interactions are part of the signal cascade enabling
bacteria to recognize the environment they are in and then turn on the cascade of
processes leading to infections [25, 26]. If these binding interactions are
inhibited/interrupted then the chances of getting infection is greatly reduced [27].
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The rapid advancement in the fields of nanotechnology and glycotechnology
offers potentially new therapeutic options for treating bacterial infections. Over the last
few years, few research groups have studied nanomaterials functionalized with
multivalent carbohydrate groups and synthetic glycoconjugates for probing bacterial
lectin-carbohydrate interactions [28, 29]. Attaching these molecules onto the surface of
nanomaterials has found numerous applications in pathogen detection/targeting,[30]
mammalian cell-receptor mimicking [31], drug delivery [32], and in anti-adhesion
therapies [33]. Specifically, carbon nanotubes [34, 35], gold nanoparticles [36, 37],
diamond nanoparticles [38], polymeric nanoparticles [39], and magnetic nanoparticles
[40-43]

were

reported

to

be

bio-functionalized

with

different

carbohydrate

sugars/glycoconjugates and were utilized for studying lectin-carbohydrate interactions in
different bacterial species. Given the excellent biocompatibility of using glycoconjugates
molecules for functionalizing nanomaterials, not many studies have been carried out that
can specifically detect and differentiate bacterial species in a mixed population both in
vitro and in vivo.
Escherichia coli (E. coli) is one of the most common types of bacteria naturally
occurring in the digestive tract of humans and animals. While most of the E. coli strains
are harmless to humans and animals, there are few E. coli serogroups that are mainly
responsible in causing infections. E. coli belonging to the enterotoxigenic (ETEC) group
is responsible for causing traveler’s diarrhea in humans and bloody diarrhea in neonatal
calves, pigs and lambs [44-46]. The prevalence of the serogroups and presence of
adhesins are considered to be the primary factors that facilitate intestinal colonization of
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ETEC. ETEC adhere to small intestinal microvilli membranes in vivo via adhesins that
recognizes specific carbohydrate receptors and produce enterotoxins that act on
enterocytes eventually causing diarrhea [47]. Recently, numerous studies have reported
an increase in multi-drug resistance of ETEC strains associated with the inclusion of
growth-promoting antibiotics in animal feed [48, 49]. E. coli K99 (EC K99) is one of the
commonly found ETEC strains in newborn farm animals responsible for causing
colibacillosis [50]. EC K99 has unique adhesins that can specifically recognize and attach
to sialic-acid based glycolipid receptors present on the ileal villus epithelium of the small
intestine [51, 52]. If these binding interactions are inhibited/interrupted, the chances of
getting infection are greatly reduced. Our previous studies have shown that nanoparticles
functionalized with specific sialic-acid derivatives resulted in nanoparticles-induced
aggregation of EC K99 along with excellent biocompatibility [36, 41].
In this study, it is hypothesized that multi-anchored magnetic nanoparticles
conjugated with sialic-acid moieties that mimic host-cell receptors specific for EC K99
adhesins, would induce rapid clustering of EC K99 in the presence of these nanoparticles,
and when such bacteria-nanoparticles aggregates are exposed to AMF, it would result in
enhanced and selective inactivation/killing of EC K99. Our results demonstrate a
clinically significant ~3-log reduction in CFU [53] of EC K99 in the presence of GM3MNPs used in conjunction with AMF. To our knowledge, it is for the first time that
sialic-acid derived glycoconjugate functionalized magnetic nanoparticles have been
employed for specific killing of target bacteria in the presence of AMF. This study serves
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as proof-of-concept that a high degree of selective bacterial killing can be obtained
without using traditional antibiotics.

2. Experimental Section:
Synthesis of Magnetite Nanoparticles: Magnetite nanoparticles were synthesized
via thermal decomposition of an organometallic precursor in a high boiling point organic
solvent [54]. Iron (III) acetylacetonate (Alfa Aesar, 99%) (1.074g) was combined in a 3neck round-bottom with oleic acid (Alfa Aesar, 90%) (15ml) serving as both the solvent
and the stabilizing ligand. The vessel was initially purged with N2 after which flow was
adjusted to 0.1 L/min ensuring an inert environment. The vessel was then heated to
350°C and left to react for 3 hours. At 3 hours, the reaction was quenched by removing it
from heat, and left to cool under inert atmosphere. The resulting particles were dispersed
in minimal hexanes and precipitated using a mixture of 3:1 ethanol (Fisher, Anhydrous)
to acetone (Alfa Aesar, 99.5%) (x3). Particles were dispersed in toluene (VWR, 99.5%)
and run through an organic based GPC column (Bio-rad S-X polystyrene beads) to
further remove excess oleic acid ligand [55]. TEM and size analysis was then done on the
particles to ensure size specificity.
Synthesis of Alkyne-PEO-PAA-Dopamine [19]: Poly(ethylene oxide) (PEO)
synthesis: Ethylene oxide (Sigma Aldrich, 99.9%) distilled into a high pressure Parr
reactor. Na-benzylphenone still dried tetrahydrofuran (THF, EMD Millipore, 99.9%) was
injected along with a predetermined amount of an anionic initiator potassium bistrimethyl
silyl amide (Sigma Aldrich, 1M in THF). The reaction was allowed to run for 72 hours
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and was subsequently terminated by opening the reactor to atmosphere. The synthesized
PEO was precipitated with diethyl ether (VWR, 99.9%) and washed (3x) by dispersing it
in chloroform, precipitating the polymer, centrifuging it at 15,000 RCF for 10 minutes
and pouring off the residual supernatant. The PEO was then dried under vacuum
overnight. HNMR was performed to calculate molecular weight as well as to confirm the
presence of the protected amine end-group.
Under dry N2 atmosphere, hetero-functional PEO and sodium hydride (Sigma
Aldrich, 95%), in slight excess, were dissolved in dry THF. This was allowed to react for
30 minutes before an excess of propargyl bromide (Sigma Aldrich, 80% in toluene) was
added drop-wise to the solution over 15 minutes. Once all of the propargyl bromide was
added, the solution was allowed to stir for 12 hours at room temperature. The polymer
was then purified by dissolution in chloroform and precipitation with diethyl ether (x3)
and dried under vacuum for 12 hours. HNMR was performed to confirm the presence of
an alkyne.
Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid
(VWR) in methanol (VWR, 99+%) and allowed to react for 4 hours. The polymer
methanol solution was diluted with DI water and the deprotected PEO was extracted (3x)
with 50ml chloroform from which it was precipitated with diethyl ether and dried under
vacuum. HNMR was performed to confirm the loss of the trimethylsilyl group.
Coupling of the PEO to the poly(acrylic acid) (PAA, Sigma Aldrich Mn=1,800) was done
by dissolving both in dry N,N-dimethylformamide (DMF, Sigma Aldrich, 99.8%) in a 5:1
ratio. To this 1.1 excess (N-(3-dimethylaminopropyl)-N’-ethylcarodiimide hydrochloride
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(EDC, TCI, 98%) as well as catalytic amounts of 4-(dimethylamino)pyridine (DMAP,
Alfa Aesar, 99+%) were added. The solution was allowed to stir for 12 hours. The
solution was filtered, further purified by dissolution in chloroform following precipitation
with diethyl ether (x3) and then dried under vacuum. HNMR was done to confirm PEOPAA coupling.
Attachment of the anchor group: Dopamine hydrochloride (Alfa Aesar, 99%) was
dissolved in DMF along with a 10% molar excess of triethylamine (Alfa Aesar, 99%) and
allowed to stir for 30 minutes. In a separate round-bottom the PEO-PAA was dissolved in
DMF along with EDC and catalytic amounts of DMAP. To this the dopamine
hydrochloride solution was added and the combined solution was allowed to stir for 12
hours. The solution was then filtered, purified by dissolution in chloroform then
precipitated in diethyl ether. The final product was dried under vacuum and analyzed via
HNMR and IR to confirm the presence of the catechol.
Ligand Exchange [17]: Both magnetite nanoparticles as well as the PEO-PAAdopamine were suspended separately in 5ml of chloroform. The particles were at an
approximate concentration of 3mg/ml of Fe and the polymer at approximately 40mg/ml.
The polymer was then transferred to a scintillation vial capped with a septum and placed
in a sonication bath. The bath was turned on and over the course of 15 minutes the
magnetic nanoparticle solution was injected into the polymer solution. Once injection
was finished, the combined solution was allowed to further sonicate for 15 minutes. The
solution was then removed and put on a shaker table for 72 hours. The chloroform was
then removed via rotary evaporator and further dried under vacuum. Deionized water (DI
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H2O) was then added and the vial was sonicated to help mediate suspension into the
water. The water-based particles were then filtered through a 0.2-micron nylon filter to
ensure large aggregates were not present. The solutions were then run through a GPC
column (Bio-Rad P polyacrylamide beads) to separate excess polymer from the water
dispersible particles.
Click Chemistry [56]: The Cu(I) catalyzed Huisgen 1,3-dipolar cyclo-addition
between the terminal polymer alkyne and the azido-GM3 was done in the aqueous phase
with the azido-GM3 being the limiting reagent. A 2 mol% solution of Cu(II) sulfate
(Sigma Aldrich, 99%) was combined with equivalent molar amounts of the THPTA
(synthesized according to Hong et al.) Cu chelating ligand and let to react for 10 minutes
[57]. This was then transferred into the aqueous alkyne-particle suspension and the azideGM3 was then added. After both additions a 10mol% aqueous solution of (+)-sodium Lascorbate (Sigma Aldrich 98+%) was added to facilitate the reduction of Cu(II) to Cu(I).
The click reactions were left at room temperature for 12 hours, and were then purified
using size exclusion chromatography [55].
Dynamic Light Scattering (DLS) and Zeta Potential Measurements: DLS was
performed on the PEO-coated and GM3-coated magnetic nanoparticles to determine their
hydrodynamic radius. The nanoparticle suspensions were diluted in water and placed into
a cuvette. Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to
determine the intensity average size distribution and z-average diameter. Zeta-potential
measurements of these nanoparticle suspensions were also determined using the same
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instrument. The suspensions were diluted with water and added into zeta-cell and three
measurements were taken at 25°C.
Fourier Transform Infrared Spectroscopy (FTIR): Fourier transform infrared
(FTIR) spectroscopy microscopy was done using a Thermo-Nicolet Magna 550 FTIR
spectrometer equipped with a Thermo-NicPlan FTIR microscope. 16 Scans were done for
both the sample and the background. Samples were prepared by dropping a small amount
of the water suspended sample on a germanium plate and left to dry under a heat lamp for
20 minutes. FTIR was done on the resulting films.
Iron Concentration Determination: 50 µl of magnetite suspension was dissolved
in concentrated HCl, reduced and complexed with 1,10-phenanthroline (Sigma-Aldrich,
99%). UV-VIS was then performed to determine the amount of iron in the known volume
[58, 59].
AMF Treatment of Bacterial Strains in the Presence of MNPs: As reported in
our previous study [41], E. coli K99 (EC K99) was transformed with plasmid pGREEN
(Carolina Biological Supply Company, NC, USA) carrying ampicillin-resistance marker
gene. Avirulent E. coli O157:H7 strain B6914 (EC O157) was modified to be rifampicin
resistant (100 µg/ml; TCI America, OR, USA) through gradient-plate technique as
previously described [60]. EC K99 strain was routinely grown in tryptic soy broth/tryptic
soy agar (TSB/TSA; EMD Millipore, MA, USA) supplemented with ampicillin (100
µg/ml; TCI America, OR, USA) and EC O157 strain was grown in tryptic soy
broth/tryptic soy agar (TSB/TSA) supplemented with rifampicin (100 µg/ml). For AMF
treatment experiments, bacterial cultures were grown overnight under shaking conditions
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(250 rpm) at 37°C in TSB supplemented with appropriate antibiotics. Later, the bacterial
cells were washed and centrifuged thrice in 1X sterile phosphate buffer saline (PBS).
Approximately, 5 x 107 CFU of bacterial cells were suspended in 1X PBS based on
optical density (OD600) readings. Both the bacterial strains were mixed with different
types of MNPs and at different concentrations of MNPs in a sterile microcentrifuge tube
and this mixture was incubated at room temperature for 30 minutes under gentle shaking
conditions to facilitate the binding interactions between bacterial adhesins and MNPs
[41]. At the end of incubation time-period, the mixtures of MNPs and bacteria were
transferred to sterile glass vial. This vial was then placed in chamber of the alternate
magnetic field generating instrument (EasyHeat Induction Heating System Ameritherm©) that is covered with 5-turn induction coil, which was connected to
polycarbonate recirculating water-bath for maintaining the sample temperature (37°C)
[61]. A fiber-optic temperature probe (Neoptix™) was inserted inside this chamber to
continuously monitor the temperature. The working conditions of the AMF instrument
for the experiments were as follows: 480 Amps current, 207KHz frequency and magnetic
field strength of 31 KA/m. The field was measured using an AC magnetic field probe
(AMF Life Systems, Auburn Hills, MI). The vial containing the mixture of MNPs and
bacteria was then exposed to AMF treatment for different durations (30, 60, and 120
minutes). Different groups of control experiments were as follows: 1) mixture containing
only bacterial strains suspended in 1X PBS; 2) mixture containing bacteria and MNPs but
no AMF exposure. After AMF treatment, the above-mentioned mixture was serially
diluted in 1X sterile PBS and 100 µl of sample from each dilution tube was spread-plated
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onto sterile TSA petri plates supplemented with appropriate antibiotics. Later, the TSA
plates were incubated overnight at 37°C. Finally, the grown colonies on the TSA plates
were counted and compared with control group plates and the reduction in colony counts
was expressed as colony forming units per ml.
AMF Treatment of Mixed Bacterial Cultures in the Presence of MNPs: To
determine the targeted specificity of GM3-MNPs against EC K99 in mixed-culture
conditions, both the strains of EC K99 (concentration - 5 x 107 CFU) and EC O157
(concentration - 5 x 107 CFU) were mixed in a single microcentrifuge tube. GM3-MNPs
(650 µg/ml) were added to this mixture and the tube was incubated for 30 minutes at
room temperature under gentle shaking conditions. Later, AMF treatment (time - 120
minutes) was applied to this tube as mentioned earlier. Control groups included 1) adding
PEO-MNPs to mixture containing both strains of bacteria in the same tube and
exposing/not exposing them to AMF; 2) adding GM3-MNPs to tube containing both
bacterial strains but no AMF; 3) AMF exposure to tube containing only bacterial strains
and no MNPs. Post-treatment, this mixture was serially diluted in 1X PBS and 100 µl of
each dilution was spread plated in triplicates onto TSA plates supplemented with
appropriate antibiotics. The petri plates were incubated overnight at 37°C and CFU
reduction was compared to control group plates.
Transmission Electron Microscopy (TEM) of Bacterial Strains: TEM imaging
of bacteria was performed in order to study the interaction of MNPs and bacterial cellsurface. The samples were prepared according to modified protocol [41, 62]. Post AMF
treatment of bacterial cells (MNPs concentration - 650 µg/ml), the mixture samples were
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removed from the glass vial and centrifuged at 7000 x g for 5 minutes. Later, the
supernatant containing unbound MNPs was removed and the pellet was washed with 1x
PBS in repetitive centrifugation cycles (3 times). After the final wash, the pellet
containing MNPs and bacteria was fixed in cacodylate-buffered glutaraldehyde (3%,
pH~7.2; Electron Microscopy Sciences, PA, USA) at 4°C for 12 hours. Subsequently, the
sample was again washed in the cacodylate buffer thrice. 5 µl of the sample was dropped
onto carbon-coated copper grid and was allowed to air dry for 4 hours. Finally, the
sample was stained with 2% uranyl acetate (Electron Microscopy Sciences, PA, USA)
solution for 15 seconds and blotted dry with filter paper. TEM images were taken on
Hitachi H-7600 at 120 KV accelerating voltage and magnification ranging from 10,000X
to 200,000X.
Bacterial Live/Dead Fluorescence Assay: To qualitatively determine the cell
membrane integrity of bacterial cells, Live/Dead fluorescence assay were performed
using BacLight™ Bacterial Viability Kit (L7007, Molecular Probes, Invitrogen, OR,
USA). Freshly grown cells of EC K99 and EC O157 (5 x 107 CFU) in 1X PBS were
mixed with PEO-MNPs and GM3-MNPs (Concentration - 650 µg/ml) separately in
different microcentrifuge tubes. The mixture was allowed to incubate at room
temperature for 30 minutes with gentle mixing after every 5 minutes. The tubes were then
exposed to AMF therapy for 120 minutes. The samples were then prepared according to
manufacturer’s protocol. Later, both fluorescent dyes i.e. SYTO 9 and Propidium Iodide
were added to the samples. Finally, the samples were viewed under fluorescence
microscope under different filters (SYTO 9 - Excitation/Emission - 485/510 nm;
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Propidium Iodide - Excitation/Emission - 485/630 nm) at 400X magnification. The
images obtained under different filters were merged in ImageJ software (NIH, USA).
Control group samples were not exposed to MNPs/AMF.
Microbial ATP Cell-Viability Assay: To measure the overall intracellular ATP
levels of bacterial species (EC K99 and EC O157) before and after AMF treatment in the
presence/absence of MNPs (concentration - 650 µg/ml, AMF treatment time - 120
minutes), microbial BacTiter-Glo™ (Promega, Madison, WI) assay kit was used [23].
The assay was performed according to manufacturer’s protocol with a small modification
for samples containing MNPs. After AMF treatment of bacteria in the presence of MNPs,
the samples were centrifuged at 10,000 x g for 5 minutes. The supernatant containing
unbound MNPs was removed and the resultant pellet was washed with 1X PBS thrice in
subsequent centrifugation cycles. Finally, the samples were suspended back in 1X PBS
and the entire assay was performed in 96-well white-flat bottom plates (Corning®) in
triplicates. Also, wells containing MNPs without any bacterial cells were used as control
blanks to check for MNPs interference with the assay reagent, if any. At the end of this
assay, the plate was read in a micro-plate reader with luminescence capability (Synergy
Hybrid H1, Biotek®) and the obtained results were expressed in relative luminescent units
(RLUs).
Statistical Analysis: All the statistical analysis was performed using Graphpad
Prism software (V 5.0, CA, USA). All the experiments were done in triplicates and data
are expressed as Mean±SD. Statistically significant differences between the groups were
evaluated by performing ANOVA. Post hoc group comparisons were calculated through
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Bonferroni post-tests. Results showing P values of ≤0.05, <0.01, and <0.001 were
considered to be statistically significant.

3. Results and Discussion:
3.1. Synthesis of GM3-MNPs:
Magnetite nanoparticles were synthesized using a one-pot thermal decomposition
of iron (III) acetylacetonate and oleic acid [1, 2]. Particles had an average diameter of
23.7 nm with a standard deviation of 1.55 nm (Figure 3.2 A and B). The moment vs. field
(MvH) (Figure 3.3) measurement was done on the particles to confirm the superparamagnetic behavior of the MNPs. Polymer design was based on work by Stone et al.
where a multi-anchored binding approach showed increased stability in comparison to
polymer ligands with a single binding moiety (figure 3.1) [3].
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Figure 3.1 Left: 1) Anionic ring opening of ethylene oxide, 2) alkyne functionalization with propargyl bromide, 3)
deprotection of primary amine, 4) coupling of PEO to PAA, 5) coupling of dopamine hydrochloride to the PEO-PAA.
Right: Click reaction between polymer coated particles and GM3 molecule.

A

B

Figure 3.2 Magnetite nanoparticles as synthesized before functionalization with PEO-PAA-dopamine polymer. A –
Representative TEM image of the particles. B – Histogram depicting the particle size distribution.

Figure 3.3 Moment vs. Field (MvH) loop showing the superparamagnetic behavior of the magnetite nanoparticles
(Msat ~ 53 emu/g Fe).

In this work, however, the chosen catechol was not nitroDOPA but dopamine. HNMR of
the polymer was used to confirm both the structure and molecular weight of the PEOPAA-dopamine macromolecule (Figure 3.4). By using the multi-anchored approach, the
stability in salt and protein buffer solutions is retained even when using dopamine as the
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anchoring group [4, 5]. Hydrodynamic diameter and zeta potential of the PEO-MNPs
before and after click-coupling of GM3 are reported in Table 3.1.

Figure 3.4 HNMR of the final PEO-PAA-dopamine - PAA backbone protons at 1.39 ppm - 1.08 ppm. Alkyne protons
at 4.18 ppm and 2.42 ppm. PEO repeat protons at 3.62 ppm. Dopamine aromatic proton signal partially masked by the
CDCl3 peak, with alkane protons showing up at 2.8 ppm. Reference was tetramethylsilane at ~0 ppm.

Hydrodynamic Diameter Z Avg.
(nm)
PEO-MNPs
GM3-MNPs

78.8
88.8

Zeta-potential
(mV)
-8.73
-7.68

Table 3.1 Dynamic light scattering and zeta-potential measurements - Hydrodynamic diameter and zeta potential as
measured by dynamic light scattering before and after GM3 conjugation.
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The specific absorption rate (SAR) value for the MNPs was measured to be 53.4 W/g
(bulk temperature rise of solution from 37°C to 42°C), which is similar to the value for
magnetite reported by Ma et al [6]. The increase in the hydrodynamic diameter indicates
the GM3 glycoconjugate was successfully coupled to the PEO-MNPs. Attenuated total
reflectance Fourier transformed infrared spectroscopy (ATR-FTIR) also confirmed the
GM3 coupling went to completion with the disappearance of the azide peak from GM3 at
~2110 cm-1 and the appearance of a broad alcohol peak in the GM3-MNPs spectrum from
3620-3170 cm-1 (Figure 3.5) [7].

Figure 3.5 FTIR spectra of particles before GM3 conjugation (A), GM3 molecule (B), and after conjugation (C). The
lack of the azide peak in C at 2100 cm-1 indicates purification of unbound GM3 after conjugation was successful.
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3.2 MagMED Inactivation of Bacteria:
The efficacy of GM3-MNPs for specific inactivation of ETEC K99 via MagMED
was compared to that of enterohaemorrhagic Escherichia coli (EHEC) O157:H7 strain
since the two strains showed different receptor-binding specificities and EHEC O157:H7
strains are rarely harbored by pigs [8]. Another E. coli strain ORN178 expressing
mannose-binding type-1 fimbrial FimH adhesins [9-13] was also evaluated and served as
a negative control (data not shown). The MagMED inactivation of bacteria was assessed
using a colony forming unit (CFU) reduction assay to determine the number of viable
cells (CFUs) remained after treatment.

3.2.1 MagMED Inactivation of EC K99:
The efficacy of AMF mediated killing of the target bacteria, EC K99, in the
presence of GM3-MNPs in a concentration- and time-dependent manner was evaluated.
GM3-MNPs were mixed with EC K99 and incubated at room temperature for 30 minutes
to facilitate the binding between GM3 molecules present on the surface of GM3-MNPs
and adhesin molecules of EC K99 [7]. PEO-MNPs were used as an internal control group
to evaluate the role of the targeting moiety GM3. The magnetic field and frequency used
in the AMF therapy remained constant for all treatment groups (31 kA/m and 207kHz).
Figure 3.6 A shows the final counts of CFU/ml of EC K99 after treatment. The reduction
in CFU/ml was found to be both time and MNPs concentration dependent. After 30
minutes of AMF treatment, ~1-log reduction in CFU/ml of EC K99 was observed at a
particle concentration of 650 µg Fe/ml. After 60 minutes of AMF treatment, a significant
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~2-log reduction of EC K99 (p<0.01) was observed for both 280 µg Fe/ml and 650 µg
Fe/ml concentrations of GM3-MNPs. Finally, at the end of 120 minutes of AMF
treatment, an extremely significant ~3-log reduction in CFU/ml of EC K99 (p<0.001)
was achieved with particle concentrations of 650 µg Fe/ml. Moreover, no significant
killing of EC K99 was observed in experimental groups not exposed to AMF (Figure 3.7
A) indicating the non-toxicity of PEO-MNPs and GM3-MNPs to EC K99.

Figure 3.6 Colony Forming Unit (CFU) of E. coli strains after AMF treatment at different concentrations of MNPs and
different time-intervals; A - CFU/ml of EC K99 after AMF treatment; B - CFU/ml of EC O157 after AMF treatment.
Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA); * p-value <0.05, ** pvalue <0.01, and *** p-value <0.001
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Figure 3.7 CFU/ml assay to determine viability of E. coli strains in the absence of AMF at different concentrations of
MNPs and at different time-intervals: A - CFU/ml of EC K99 in the absence of AMF; B - CFU/ml of EC O157 in the
absence of AMF. Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA).

Thus, targeted approach in AMF exposure can explain such effective reduction in
CFU/ml of EC K99. Several research studies have shown similar results in reduction of
bacterial population through antibody-targeted photo-inactivation process via nearinfrared laser (NIR) in the presence of nanoparticles in both in vitro and in vivo settings
[14-16]. In our previous work, we have shown that sialic-acid sequences of GM3
molecule (Neu5Ac(α2-3)-Gal-(β1-4)Glcβ-sp) can specifically interact with S-type
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fimbrial proteins/adhesins present on the outer surface of EC K99 and induce rapid
clustering of EC K99 [7, 17]. The presence of FanC, a major protein sub-unit present in
S-type fimbriae, is primarily responsible for the specific attachment of EC K99 onto the
ganglioside receptors, which are present on the host-cell surface [18]. Therefore, it is
likely that GM3-MNPs-induced bacterial aggregation plays a major role in the applied
method. Since GM3-MNPs are attached to or are in extremely near vicinity of EC K99,
one can expect to see increased delivery of energy from the particles into the bacterial
cells. Some reports have also suggested highly localized temperature increase taking
place in the biological systems in the presence of MNPs when using AMF [19-21]. For
example, Huang et al. functionalized the surface of MNPs with fluorophores that act as
molecular temperature probes while remotely activating ion channels/neurons in the
presence of AMF [22]. Also, the observed drug release due to phase changes in the
polymer near the surface of the particle suggests a local temperature increase [23]. In
these studies, too, the overall temperature of bulk particle suspensions remained constant
or increased marginally. However, the exact mechanisms of how energy from the particle
interferes with these pathways are still unknown and are in need of better
characterization.
In the present study, the experimental group comprising of 140 µg Fe/ml that
underwent AMF treatment did not show significant reduction in CFU/ml of EC K99 after
120 minutes of exposure. One possible explanation for this might have to do with the
number of particles present in different concentrations of the GM3-MNPs. The lowest
concentration group would have the least amount of MNPs. Thus, they might not be able
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to efficiently deliver the energy of the MNPs into the bacterial cells. PEO-MNPs at all
concentrations and all time-points did not induce significant decrease in the colony
counts of EC K99.
3.2.2 MagMED Inactivation of EC O157:
Figure 3.6 B shows the overall reduction in CFU/ml of EC O157 after exposure to
AMF in the presence of PEO-MNPs or GM3-MNPs. A ~1-log reduction in CFU/ml was
observed with both PEO-MNPs and GM3-MNPs at particle concentration of 650 µg
Fe/ml for 60 and 120 minutes. All other MNPs concentrations and time-points showed no
significant reduction in colony counts of EC O157. No reduction in CFU/ml of EC O157
was observed in the absence of AMF (Figure 3.7 B) indicating the non-toxicity of PEOMNPs and GM3-MNPs to EC O157. Several groups have observed certain degree of
non-specific electrostatic interactions occurring between bacteria and nanoparticles when
mixed with relatively higher concentrations of nanoparticles [24, 25]. Hence, it is
possible that due to such non-specific interactions along with high MNPs-to-bacteria
ratio, few MNPs might come in contact or close proximity with EC O157 resulting in
delivery of some magnetic energy into these cells causing a limited ~1-log reduction in
CFU. Bacterial control groups exposed to AMF in the absence of MNPs showed no
changes in the overall CFU/ml after 120 minutes of exposure (Figure 3.8 A and B)
indicating the non-lethal effect of AMF.
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Figure 3.8 Survival rate of E. coli strains at 37°C in the absence of MNPs at different time-intervals: A - CFU/ml of
EC K99 in the absence/presence of AMF; B - CFU/ml of EC O157 in the absence/presence of AMF. Data is expressed
as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA).

Recently, Nguyen et al. conducted a similar type of study wherein they showed
that iron-oxide nanoparticles could rapidly induce biofilm dispersal in Pseudomonas
aeruginosa (P. aeruginosa) through application of an alternating magnetic field [26].
Their study showed rapid increase in the temperature of buffer solution when
nanoparticles were mixed with them and exposed to magnetic field. Similarly, another
study reported 4-log reduction in biofilm of P. aeruginosa when exposed AC magnetic
field in the presence of iron-oxide nanoparticles [27]. The authors have attributed this
reduction in biofilm due to quick increase in bulk temperature of the system through
magnetic hyperthermia. Thomas et al. used magnetic fluid hyperthermia in the presence
of carboxylic-acid stabilized iron-oxide nanoparticles and achieved ~7-log reduction in
population of Staphylococcus aureus [28]. In all of the aforementioned studies, the
killing/inactivation of bacterial species/biofilms was attained solely due to drastic
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increase in the bulk temperature of the working system through nanoparticles and
hyperthermia. It would be worthwhile to note that the aforementioned studies were
conducted in the presence of relatively high concentrations of MNPs (ranging from 1
mg/ml to 50 mg/ml) and higher instrument frequencies (e.g., up to 1.05 MHz). Using
such high concentrations of MNPs in humans might cause serious concerns with regard
to toxicity of MNPs. Also, none of the above listed studies utilized any kind of targeting
moiety on nanoparticles for attaining specificity. On the other end, this work
demonstrates significant killing of EC K99 at much lower concentrations (maximum
concentration - 650 µg Fe/ml) and at relatively benign frequencies (i.e., 207 kHz). These
results further support our hypothesis that the combination of magnetic fields and
presence of GM3-MNPs are responsible for reduction in CFU/ml of EC K99 via targeted
AMF therapy. The reported CFU reduction within 120 minutes (i.e., 3-log in 2 hours)
treatment compares favorably to conventional antibiotic treatments. For examples, Silva
et al. reported that ciprofloxacin at concentrations corresponding to 1x MIC (Minimal
Inhibitory Concentration) reduced E. coli population by 1-log over a 24-h study while at
2x and 4x times the MIC value, they observed a ~2.5-log reduction in the first 2 hours
and a 4-log reduction after 24 hours of treatment [29]. In a similar study, Drago et al.
observed no reduction of E. coli population at 1x MIC with levofloxacin or ciprofloxacin
over a 24-h period while a 2-log and 3-log reduction at 4x MIC was observed 3 hours and
24 hours after treatment, respectively [30]. It is conceivable that with fine-tuned
MagMED treatment regimen, it is possible to improve the treatment outcomes of
infections caused by multiple-drug resistant bacteria.
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As mentioned earlier, a moderate temperature increase (37°C to 42°C) was
observed in the bulk particle suspension while measuring SAR values in the presence of
magnetic field. To prove that the significant log-reduction of EC K99 is not due to
temperature increase alone, a CFU/ml assay on both the E. coli strains at elevated
temperature of 43°C was performed. The bacterial strains were incubated with PEOMNPs and GM3-MNPs for 120 minutes and this mixture was kept inside the holding
chamber of the AMF instrument by maintaining a constant temperature of 43°C for 120
minutes in the absence of magnetic field. As seen in Figure 3.9 A and B, no significant
changes in CFU/ml of EC K99 and EC O157 were observed after exposing the bacteria to
MNPs and at elevated temperatures for 120 minutes. This strongly suggests that
inactivation of the bacteria cannot be attributed to temperature alone.

Figure 3.9 Evaluating the effect of temperature increase on killing-rate of E. coli strains in the absence of AMF (time 120 minutes): A - Killing-rate of EC K99 at 37°C/43°C in the presence of MNPs (concentration - 650 µg Fe/ml); B Killing-rate of EC O157 at 37°C/43°C in the presence of MNPs (concentration - 650 µg Fe/ml). Data is expressed as
Mean ± SD (n=3); Statistical analysis - 2-Way Analysis of Variance (ANOVA).
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3.2.3 MagMED Inactivation of EC K99 and EC O157 in Mixed-Culture:
Pathogens interact with host in a heterogeneous environment; the efficacy of
utilizing MagMED for killing of the target bacteria EC K99 was evaluated in a mixedculture condition. Both strains of the E. coli cultures were mixed in the same container at
equal concentrations and added either the GM3-MNPs or the PEO-MNPs at a maximum
concentration of 650 µg Fe/ml. These mixtures underwent the same AMF exposure as
described earlier for 120 minutes and the CFU/ml reduction assay was done to determine
the inactivation rates of both strains of E. coli. As seen in Figure 3.10 A, a significant
~2.5-log reduction (p<0.001) in CFU/ml of EC K99 in the presence of GM3-MNPs and
AMF exposure was observed. The other mixed culture containing PEO-MNPs did not
show significant difference in CFU/ml numbers compared to controls in the
absence/presence of AMF. In addition, ~1-log reduction (p<0.05) in CFU/ml of EC O157
was seen when the mixed-cultures were added with PEO-MNPs or GM3-MNPs and
underwent AMF treatment for 120 minutes (Figure 3.10 B). This reduction in CFU/ml of
EC O157 is comparable in both mixed-culture and pure-culture experiments. Compared
to CFU/ml assay results of EC K99 in pure bacterial culture experiments where a ~3-log
reduction was observed, the results obtained from mixed-culture experiments showed a
~2.5-log reduction. This minor difference could be the result of a change in nanoparticleto-bacterium ratio in mixed-culture experiments. Since the nanoparticle-to-bacterium
ratio was reduced by half under mixed-culture settings, the probability of GM3-MNPs
interacting with EC K99 as well as EC O157 is also slightly reduced than in pure culture
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settings. To the best of our knowledge, this is the first report wherein killing of targeted
bacterial strains via MagMED has been demonstrated in mixed-culture settings.

Figure 3.10 Colony Forming Unit (CFU) of E. coli strains in mixed-culture conditions exposed to AMF for 120
minutes in the presence of MNPs (650 µg Fe/ml); A - CFU/ml of EC K99 after AMF treatment; B - CFU/ml of EC
O157 after AMF treatment. Data is expressed as Mean ± SD (n=3); Statistical analysis - 2-Way Analysis of Variance
(ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001.

3.3 Investigating Interactions between GM3-MNPs and EC K99 via Transmission
Electron Microscopy (TEM):
One of the many causes for inactivation/killing of bacterial cells could be due to
physical damages of bacterial cell membrane that results from the presence of different
types of nanoparticles [31, 32]. In order to investigate the bacterial-nanoparticle
interactions between GM3-MNPs and EC K99, TEM analysis on the samples was
performed before and after AMF exposure. Since the maximum reduction in CFU/ml of
EC K99 was achieved in the presence of 650 µg Fe/ml MNPs after 120 minutes, the same
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experimental conditions to investigate if AMF exposure can exert any specific
morphological changes on the bacterial cell membrane of EC K99 was followed.
Visualizing TEM images, highly specific interactions taking place between GM3-MNPs
and outer membrane of EC K99 was observed. Figure 3.11 B shows the extent of GM3MNPs specifically attached to EC K99. The entire cell-surface of the bacteria was
covered with GM3-MNPs before applying AMF. There was no visible morphological
change seen on the bacterial cell surface of EC K99, which could also indicate that the
nanoparticle system does not have an apparent inherent toxicity by itself towards
bacteria.

Figure 3.11 TEM images of GM3-MNPs induced bacterial membrane damage of E. coli strains: A, B, E, F - Before
AMF, and C, D, G, H - after AMF treatment for 120 minutes. Concentration of MNPs - 650 µg Fe/ml. Scale bar is 500
nm.
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Also, GM3-MNPs induced bacterial aggregation of EC K99 was clearly visible in TEM
images (Figure 3.12 B). In contrast, after applying AMF, the cell structure of EC K99
was seen to be extremely damaged as seen in Figure 3.10 D. Please also note that the
diameters of EC K99 were reduced to less than 0.5x0.25 µm from the typical 1x0.5 µm.
The nanoparticles were found internalized in cells of EC K99 after rupturing the cell
membrane. Concurrent findings were also reported in a few studies with regard to
destruction of bacterial cell membrane via targeted photo-thermal lysis in the presence of
nanoparticles [33, 34]. Even after AMF exposure, GM3-MNPs were found to remain
attached onto bacterial cell debris, which suggests strong binding interactions between
GM3-MNPs and adhesin molecules of EC K99 present on the bacterial cell surface.
Interestingly, it was observed that both the polar ends of EC K99 were found to be much
more deformed and broken (Figure 3.12 A and B). However, not much damage was seen
towards the horizontal length of EC K99. A large quantity of cell membrane debris was
observed in the TEM analysis suggesting that EC K99 would have undergone thermal
lysis after AMF exposure possibly due to highly localized temperature increase.
Moreover, both PEO-MNPs and GM3-MNPs did not show any substantial attachment to
EC O157 cells (Figure 3.11 E to H). Even the cell membrane morphologies looked
similar to control group cells that were exposed to AMF without any MNPs. Thus, the
TEM analysis and CFU/ml assays support our initial findings regarding the specific
interactions occurring between GM3-MNPs and EC K99 and that GM3-MNPs found on
bacterial surface of EC K99 play an important role in lysing the bacterial cells
(bactericidal) when exposed to AMF.
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Figure 3.12 TEM imaging of EC K99 cells after AMF treatment in the presence of GM3-MNPs: A - EC K99 cells
showing lysis/breakage of their polar ends (Scale bar - 100 nm); B - EC K99 cells showing aggregation and breakage
induced by presence of GM3-MNPs and AMF (Scale bar - 500 nm). Magnification ranges between 50,000X to
150,000X.

3.4 Bacterial Live/Dead Fluorescence Assay:
One of the common assays employed to check the membrane integrity of bacterial
cells is to use propidium iodide dye [35]. Since the TEM analysis showed extensive
membrane damage of EC K99 cells after AMF treatment, to further support these results,
bacterial live/dead assays were performed. E. coli strains, after AMF exposure in the
presence of MNPs, were stained using mixture of SYTO 9 and propidium iodide dyes.
SYTO 9 is a green-fluorescent dye that stains both live and dead bacterial cells by
entering inside them. Conversely, propidium iodide can only permeate those bacterial
cells whose cell membrane structures have been compromised and stains them red. For
this assay, the bacterial strains were mixed with different types of MNPs. Figure 3.13
shows the results obtained after performing live/dead-staining assays.
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Figure 3.13 Live/Dead Staining Assay using SYTO 9 and Propidium iodide dyes. Both strains EC K99 and EC O157
are stained with mixture containing the above-mentioned dyes. The bacterial strains were initially mixed with PEOMNPs and GM3-MNPs (concentration - 650 µg Fe/ml) and then exposed to AMF treatment for 120 minutes. Live
bacterial cells appear green in color and dead cells appear red in color. All the images are merged together for both
green and red channel filters of the microscope. A, B, E, and F represent E. coli cells incubated with MNPs but without
AMF treatment. C, D, G, and H represent E. coli cells incubated with MNPs in the presence of AMF. Magnification 400X, Scale bar - 100 µm.

As clearly seen in Figure 3.13 D, more than 95% of EC K99 cells were stained
red in color after exposure to AMF in the presence of GM3-MNPs. This proves that
indeed EC K99 cells experienced extensive cell membrane damage due to AMF. Also,
~50% of EC O157 cells were stained red which suggests partial membrane damage
(Figure 3.13 G-H). In contrast, both E. coli strains stained green in color in the presence
of MNPs but without exposure to AMF (Figure 3.13 A, B, E, F). The control group of
bacterial cells in the absence of both MNPs and AMF also stained green in color (Figure
3.14 A and B). These results further support the non-toxic nature of the nanoparticles.
Several research groups obtained similar results for live/dead staining assay when
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magnetic nanoparticles were used as antibacterial agents [25, 26, 36]. These results
correlate with those obtained in CFU reduction assay wherein EC K99 and EC O157
showed ~3-log reduction and ~1-log reduction in CFU/ml, respectively, after 120 minutes
of AMF treatment in the presence of GM3-MNPs.

Figure 3.14 Live/Dead Staining Assay using SYTO 9 and Propidium iodide dyes: A - EC K99 in the absence of MNPs
and no AMF; B - EC O157 in the absence of MNPs and no AMF. Magnification - 400X, Scale bar - 100 µm.

3.5 ATP Assay:
The amount of ATP level present in any cell determines its metabolic state. In the
presence of toxic materials/chemicals, the metabolic state of the cell can change and the
intracellular ATP levels could drop because of toxicity. Higher levels of intracellular
ATP levels indicate that the cell is metabolically active and their levels directly correlate
to the actual number of bacterial cells present in the solution. Currently, several
antibiotics available in the market exert their effects on targeting bacterial membrane
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components to eradicate infections [37, 38]. To further demonstrate and explain the effect
of AMF exposure on the biochemical metabolism of the inner cell membrane, an ATP
assay based on luminescence was conducted to evaluate final ATP levels of EC K99 and
EC O157 after exposing them to AMF for 120 minutes in the presence of different types
of MNPs at their highest concentrations (650 µg Fe/ml). As seen in Figure 3.15 A, a
substantial decrease in intracellular ATP levels of EC K99 (p<0.001) after 120 minutes of
AMF treatment can be observed in the presence of GM3-MNPs only while EC K99 in the
presence of PEO-MNPs with/without AMF did not show significant changes in ATP
levels. In contrast, the intracellular levels of EC O157 were found to be slightly reduced
both in the presence of PEO-MNPs or GM3-MNPs with AMF exposure (Figure 3.15 B).
A similar decrease in ATP levels was reported in P. aeruginosa when they were
subjected to magnetic induction in the presence of iron-oxide nanoparticles [26]. One
possible explanation for reduced ATP levels in the presence of AMF exposure can be the
decline in membrane potential of bacteria, which could lead to interruption in ATP
synthesis mechanisms (e.g., reduced proton motive force), membrane depolarization and
eventually cell-death [32, 39, 40].
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Figure 3.15 Intracellular ATP levels of bacterial strains in the presence of MNPs using BacTiter Glo. A - ATP levels of
EC K99 after 120 minutes of AMF treatment in the presence of MNPs; B - ATP levels of EC O157 after 120 minutes
of AMF treatment in the presence of MNPs. Data expressed as Mean ± SD (n = 3); Statistical Analysis - 2-Way
Analysis of Variance (ANOVA). * p-value <0.05, ** p-value <0.01, and *** p-value <0.001.

It is worth noting that EC O157 when treated with AMF in the presence of PEOMNPs or GM3-MNPs resulting in similar limited level of cell damage, reductions in
viable cells and intracellular ATPs. These results indicated that the changes are
independent of the GM3 functional groups present on the surface of MNPs. The
susceptibility of EC O157 to localized temperature changes due to proximity could be
due to a lower thermal decimal reduction time (D-value) of EC O157 than that of EC K99
[41].

92

4. Conclusion:
Proof-of-concept multi-anchored glycoconjugate GM3-MNPs that have high
affinity to adhesin of EC K99 were synthesized. The prepared nanoparticle system can
specifically interact with adhesin molecules of EC K99 and cause agglutination through
nanoparticle-bacteria complex. Applying AMF treatment to such complex caused
significant reduction in viability of targeted bacteria EC K99 in both pure-culture and
mixed-cultures settings due to possible highly localized temperature increase. Exposure
to such conditions resulting in compromised membrane integrity of EC K99 as
determined through TEM imaging and Live/Dead staining. Moreover, GM3-MNPs
coupled with AMF resulted in significant decrease in the overall intra-cellular ATP levels
of the bacterium. Hence, the unique multi-anchored nanoparticle system in the presence
of AMF can be effectively used as novel non-antibiotic platform for local and selective
inactivation of the target bacteria in biological systems without affecting the viability of
nearby cells/tissues. In the event of gastro-intestinal (GI) tract infections caused by ETEC
pathogens, administered antibiotics can disrupt/destroy beneficial gut micro-flora in
addition to pathogens. It could cause various side effects in the human body along with
giving rise to antibiotic-resistant bacterial strains. The presented system can find useful
applications in treating such infections in animals and humans and in conditions when
administered antibiotics, especially those of the last-line-of-defense drugs, fail to
eradicate the infections due to drug-resistance. Future studies will involve optimization of
particle parameters including nanoparticle core-size and polymer coatings, as well as a
detailed investigation on the effects of field strength and frequency to maximize killing
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rate of clinically relevant multi-drug resistant bacterial pathogens. Additionally,
biocompatibility of our nanoparticle system will be evaluated in human cell-lines and
small animal models.
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Chapter 4
Assessing the Biocompatibility of Multi-anchored Glycoconjugate
Functionalized Magnetic Nanoparticles in Normal Human Colon Cellline CCD-18Co
[Parts of this chapter are taken directly or adapted from work published in Advanced
Functional Materials journal by Raval et al. (2017); DOI: 10.1002/adfm.201701473.
Copyrights 2017 - Reproduced by permission of John Wiley and Sons. Website link:
http://onlinelibrary.wiley.com/wol1/doi/10.1002/adfm.201701473/abstract]

1. Introduction:
In the last two decades, nanotechnology has evolved to be one of the most
promising scientific areas, which have a huge potential to drastically change the facet of
biomedical world in terms of its applicability. As a result, there has been a continuous
rise in the amount of literature reported that deals with the application of nanomaterials to
treat various human diseases [1, 2]. Application of nanomaterials in biomedical field,
commonly referred to 'Nanomedicine', has attracted huge investments (in billions) in
research & development funding both in the US and European counterparts. For example,
the annual budget of National Nanotechnology Initiative (NNI) of US government grew
exponentially from $0.5 billion in 2001 to $24 billion in 2017 [3, 4]. Some of the widely
used nanoparticles for biomedical applications include gold nanoparticles, silver
nanoparticles, magnetic nanoparticles, quantum dots, etc. These nanoparticles have been
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used for targeted drug and gene delivery (e.g., delivery of anticancer drugs), as
antibacterial agents, as vaccines, in various bio-imaging techniques like magnetic
resonance imaging (MRI), positron emission tomography (PET) & computerized
tomography (CT), and in diagnostics among several other applications [5-9]. Despite the
rapid splurge in funding of nanoparticle research aimed for treating several diseases, not
much success has been achieved in terms of their effective use in clinical settings [4, 10].
Currently, there exists a huge fundamental gap in translating the laboratory-based
results of different nanoparticles that can certainly be used in bench-to-bedside scenarios.
Some of the major factors that prevent their clinical use are difficulties in successful
synthesis of nanoparticles that have consistent physical and chemical properties, reduced
stability of nanoparticles in biological environment, poor understanding of the
interactions which occurs between nanoparticles, biomolecules, and body fluids, and
lastly the safety and biocompatibility of nanoparticles inside human body [11, 12].
Amongst all of the above stated issues, in this chapter, we will be mainly focusing on
how surface functionalization of magnetic nanoparticles can affect its interaction with
biological environment. Among various metallic nanoparticles, magnetic nanoparticles
(MNPs), on account of their small size, unique magnetic properties and high degree of
biocompatibility, have garnered major attention in nanomaterials research due to their
multitude biomedical applications, which include but are not limited to targeted drug
delivery, magnetic hyperthermia, magnetic resonance imaging, cell separation, cancer
therapy, diagnostics and pathogen detection [13-15]. In fact, MNPs are already used
clinically as MRI contrast agents for therapeutic purposes [6, 16]. Recent research efforts
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have largely concentrated on manipulating the surface chemical properties of MNPs so as
to render them high stability in biological rich environment. During the typical synthesis
procedure, the resultant MNPs are generally found to be hydrophobic in nature and hence
it is colloidically unstable in biological environment, thereby, not suitable in clinical
applications [17, 18]. Making such MNPs hydrophilic is of prime importance in order to
achieve chemically stable colloidal suspension of MNPs. For this purpose, surface
coating of MNPs is essential and functionalizing the core of MNPs by robust
monomeric/polymeric stabilizers typically does it. Also, these polymers should be
biologically inert in nature so as to provide electrostatic and or stearic repulsion and
'stealth' properties to MNPs in presence of protein-rich environment and at the same time
they should be able to circulate in the body for prolonged time duration until they reach
their targeted location without triggering body's immune response [19, 20].
Some of the commonly employed monomeric agents that can easily bind to the
core of MNPs include carboxylic acids, alcohols, sulfates, phosphates, and amines [18,
21-23]. Polymeric stabilizers utilized for surface stabilization of MNPs usually include
binding groups such as polyethylene glycol (PEG)/polyethylene oxide (PEO), alginate,
dextran, poly vinyl alcohol (PVA), chitosan, etc. [24-27]. Extensive studies have been
done on synthesized MNPs that has PEO polymer as the main stabilizing agent. PEO is
one of the universally accepted polymers that have been approved by the FDA. Some of
major advantages of attaching PEO onto nanoparticles, which make them extremely
suitable for clinical applications, are improved stability of the entire nanoparticle system
in biological environment, imparting 'stealth' properties to MNPs and extended blood
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circulation time, amphiphilic in nature, soluble in water as well as in many other solvents,
can act as carrier molecule in different pharmaceutical products and the ease of
manipulating its surface chemistry for wide-spread use in biomedical applications [17,
26, 28, 29]. However, in the presence of high salt & protein concentration, few of the
above-mentioned binding groups tend to undergo desorption process and can be easily
displaced from the surface of MNPs core (generally made up of iron-oxide). More
specifically, anionic phosphates and silicates present in bodily fluids and also on the
surface of several peptide molecules have high affinity towards iron-oxide core of MNPs
and hence can lead to colloidal instability and rapid aggregation of MNPs [17]. In order
to overcome this issue, recent studies have suggest that catechol-based anchor groups can
inhibit non-specific interactions of other reactive groups towards the iron-oxide core and
this has greatly improved the stability of MNPs in physiological fluids [30-34]. These
catechol groups frequently use dopamine-based molecules that can tightly bind to metal
oxide cores (especially Fe3O4), and can also be effortlessly attached to polymeric agents
via different chemistry routes.
Several studies have presented MNPs coated with appropriate polymer stabilizing
agents to be highly biocompatible and biodegradable in in vitro and in vivo [9, 15, 35,
36]. The main advantage of using MNPs for clinical applications is that, compared to
other nanoparticles, MNPs can be metabolized and completely removed/excreted from
the body through various systemic and cellular iron homeostasis pathways [37, 38].
However, it should be carefully noted that the biocompatibility of MNPs is highly
dependent on multitude of factors like core size, final size of MNPs, surface chemistry of
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the MNPs, adsorbed proteins on the surface of MNPs, given dosage, biodistribution, and
final localization of MNPs in the body among several others [37, 39-41]. In spite of
having excellent biocompatibility, numerous in vitro and in vivo studies have
demonstrated differential toxicity of MNPs [24, 38, 41-43]. The different toxicity
mechanisms observed in determining safe dosage levels of MNPs in cell-line studies
include impaired mitochondrial function, cytotoxicity, cell apoptosis, DNA damage and
genotoxicity, immunotoxicity, oxidative stress, disordered cell morphology, cytoskeleton
damage, cell-membrane damage, etc. [11, 24, 25, 37, 44, 45]. Other factors that influence
the toxicity levels of MNPs in in vitro conditions include type of cell-line, concentration
of MNPs, incubation time, and cellular uptake [4, 46]. To date, the majority of the cellline toxicity studies of MNPs have been largely conducted in cancer cell-line models.
Some of the commonly used ones are breast, colon, intestinal, lung, and brain cancer celllines [5, 6, 47-49]. However, using such cancer cell-lines does not always provide
reliable nanotoxicity evaluation of tested nanomaterials since these cell-lines may have
been intentionally manipulated with to make them immortal [46, 50]. Also, cancer cells
have higher proliferation rate, higher resilience to foreign objects, disorganized and leaky
blood vessels, and altered cellular signaling pathways and therefore they do not correctly
represent the physiological/biological state of normal cells [46, 51]. Hence, in-depth
toxicological studies carried out in normal cell-lines or primary cells are warranted to
fully comprehend and determine the possible toxicity mechanisms of MNPs before
further testing is done in animal models.
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Carbohydrates are important group of molecules that play vital role in numerous
biological processes in mammalian systems. Some of the key processes modulated by
carbohydrate molecules, include cell-cell communication, molecular signal transduction,
cell growth and differentiation, apoptosis, inflammation and immune responses, tumor
metastasis etc. [52-54]. Several of these carbohydrate molecules also serve as cell-surface
receptors that can recognize viral/bacterial pathogens entering into the cells. Over the last
two decades, numerous reports have utilized functionalized nanoparticles (e.g., gold
nanoparticles, silver nanoparticles, diamond nanoparticles, magnetic nanoparticles,
carbon nanotubes etc.) based on carbohydrate chemistry, which includes monosaccharide,
disaccharides, oligosaccharides, and glycan/glycoconjugate molecules [55-58]. These
studies have investigated the role of different carbohydrate molecules present on the
surface of nanoparticles in studying multivalent carbohydrate-carbohydrate interactions,
carbohydrate-lectin interactions for therapeutic purposes. Nanoparticles functionalized
with carbohydrate molecules offer many advantages compared to their monovalent forms
especially with regard to achieving high affinity constant (Ka) and increased binding
enthalpy (ΔH) due to presence of multivalent interactions [59]. On account of their high
surface/volume ratio, functionalizing numerous carbohydrate groups onto the surface of
nanoparticles is fairly easy and it also drastically increases the biocompatibility of the
entire nanoparticle system. Especially, MNPs having different physico-chemical
properties and functionalized with carbohydrates have been frequently used in various
biomedical applications such as targeted drug delivery, MRI imaging, pathogen
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detection, as vaccines, anti-adhesion therapies, bio-sensing applications, cancer
treatment, and cell-surface receptor mimicking [55-57, 59].
Few studies have described using nanoparticles functionalized with specific
lectins and carbohydrates for targeted drug delivery to colon cells [60-62]. Of late,
nanoparticles loaded with different drugs have been used as therapeutic agents for
treating inflammatory bowel syndrome (IBS) [63, 64]. Most of these treatment regimens
often involve localized and targeted drug release via orally ingested nanoparticles to the
colon region of the gastrointestinal tract (GI tract). Such approach increased the overall
efficacy of the drugs used in treating IBS by utilizing various nano-drug formulation
strategies

that

enhanced

the

uptake

of

drug-loaded

nanoparticles

into

the

inflamed/diseased region of the colon. Frequently, in the case for disease diagnosis and
evaluation of IBS, GI tract imaging is done via MRI and CT scan [65]. These imaging
techniques often include MNPs as theragnostic agents, which can act both as MRI
contrast and drug delivery agents. By utilizing nano-platform based imaging techniques,
it is possible to monitor the drug-release kinetics of nanoparticles in the GI tract. Most of
the in vitro studies that have been carried out till date to understand the cellular and
molecular interactions of nanoparticles with intestinal cells regularly use Caco-2 cells
(human colorectal adenocarcinoma) monolayers [66-69]. However, using Caco-2 cells
for such studies do not accurately reflect the physiological conditions of normal colon
cells. Even though PEG/PEO polymer used for stabilizing MNPs has been reported to
have excellent biocompatibility in numerous cell-lines and animal studies, several
research studies have deemed it to be toxic to cells [70-74]. Most of the in vitro cell-line
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studies evaluating toxicity of PEO-coated nanoparticles typically do not expose the cells
above 100-200µg/ml [37, 75]. However, it is important to understand the biological
response of cells in presence of sub-lethal and lethal concentrations of nanoparticles.
Depending on overall size, surface charge, polymer length and degree of grafting density
on nanoparticle surface, PEO can show differential toxicity.
Previous research work has shown that MNPs synthesized with dopamineanchored heterobifunctional PEO polymer (PEO-MNPs) and bio-functionalized with
sialic-acid specific glycoconjugate moiety (Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp) (GM3MNPs) can be effectively used as targeted antibacterial agents against enterotoxigenic
Escherichia coli, which is usually associated with gastroenteritis and can also trigger
post-infectious IBS [59, 76]. In this chapter, we will be focusing on evaluating the
biocompatibility of both PEO-MNPs and GM3-MNPs in normal human colon cell-line
CCD18-Co. According to author's knowledge, this is a first study which encompasses
different toxicity assays to better understand the biocompatibility of glycoconjugate
functionalized MNPs in normal human colon cells. Understanding the interactions
occurring between different MNPs and CCD18-Co cells will eventually help in
determining the safe dosage levels of these MNPs to be effectively used as novel drug
delivery agents for treating IBS and infections associated with it.
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2. Experimental Section:
Synthesis of Magnetite Nanoparticles: Magnetite nanoparticles were synthesized
via thermal decomposition of an organometallic precursor in a high boiling point organic
solvent [77]. Iron (III) acetylacetonate (Alfa Aesar, 99%) (1.074g) was combined in a 3neck round-bottom with oleic acid (Alfa Aesar, 90%) (15ml) serving as both the solvent
and the stabilizing ligand. The vessel was initially purged with N2 after which flow was
adjusted to 0.1 L/min ensuring an inert environment. The vessel was then heated to
350°C and left to react for 3 hours. At 3 hours, the reaction was quenched by removing it
from heat, and left to cool under inert atmosphere. The resulting particles were dispersed
in minimal hexanes and precipitated using a mixture of 3:1 ethanol (Fisher, Anhydrous)
to acetone (Alfa Aesar, 99.5%) (x3). Particles were dispersed in toluene (VWR, 99.5%)
and run through an organic based GPC column (Bio-rad S-X polystyrene beads) to
further remove excess oleic acid ligand [78]. TEM and size analysis was then done on the
particles to ensure size specificity.
Synthesis of Alkyne-PEO-PAA-Dopamine [79]: Poly(ethylene oxide) (PEO)
synthesis: Ethylene oxide (Sigma Aldrich, 99.9%) distilled into a high pressure Parr
reactor. Na-benzylphenone still dried tetrahydrofuran (THF, EMD Millipore, 99.9%) was
injected along with a predetermined amount of an anionic initiator potassium bistrimethyl
silyl amide (Sigma Aldrich, 1M in THF). The reaction was allowed to run for 72 hours
and was subsequently terminated by opening the reactor to atmosphere. The synthesized
PEO was precipitated with diethyl ether (VWR, 99.9%) and washed (3x) by dispersing it
in chloroform, precipitating the polymer, centrifuging it at 15,000 RCF for 10 minutes
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and pouring off the residual supernatant. The PEO was then dried under vacuum
overnight. HNMR was performed to calculate molecular weight as well as to confirm the
presence of the protected amine end-group.
Under dry N2 atmosphere, hetero-functional PEO and sodium hydride (Sigma
Aldrich, 95%), in slight excess, were dissolved in dry THF. This was allowed to react for
30 minutes before an excess of propargyl bromide (Sigma Aldrich, 80% in toluene) was
added drop-wise to the solution over 15 minutes. Once all of the propargyl bromide was
added, the solution was allowed to stir for 12 hours at room temperature. The polymer
was then purified by dissolution in chloroform and precipitation with diethyl ether (x3)
and dried under vacuum for 12 hours. HNMR was performed to confirm the presence of
an alkyne.
Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid
(VWR) in methanol (VWR, 99+%) and allowed to react for 4 hours. The polymer
methanol solution was diluted with DI water and the deprotected PEO was extracted (3x)
with 50ml chloroform from which it was precipitated with diethyl ether and dried under
vacuum. HNMR was performed to confirm the loss of the trimethylsilyl group.
Coupling of the PEO to the poly(acrylic acid) (PAA, Sigma Aldrich Mn=1,800) was done
by dissolving both in dry N,N-dimethylformamide (DMF, Sigma Aldrich, 99.8%) in a 5:1
ratio. To this 1.1 excess (N-(3-dimethylaminopropyl)-N’-ethylcarodiimide hydrochloride
(EDC, TCI, 98%) as well as catalytic amounts of 4-(dimethylamino)pyridine (DMAP,
Alfa Aesar, 99+%) were added. The solution was allowed to stir for 12 hours. The
solution was filtered, further purified by dissolution in chloroform following precipitation
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with diethyl ether (x3) and then dried under vacuum. HNMR was done to confirm PEOPAA coupling.
Attachment of the anchor group: Dopamine hydrochloride (Alfa Aesar, 99%) was
dissolved in DMF along with a 10% molar excess of triethylamine (Alfa Aesar, 99%) and
allowed to stir for 30 minutes. In a separate round-bottom the PEO-PAA was dissolved in
DMF along with EDC and catalytic amounts of DMAP. To this the dopamine
hydrochloride solution was added and the combined solution was allowed to stir for 12
hours. The solution was then filtered, purified by dissolution in chloroform then
precipitated in diethyl ether. The final product was dried under vacuum and analyzed via
HNMR and IR to confirm the presence of the catechol.
Ligand Exchange [32]: Both magnetite nanoparticles as well as the PEO-PAAdopamine were suspended separately in 5ml of chloroform. The particles were at an
approximate concentration of 3mg/ml of Fe and the polymer at approximately 40mg/ml.
The polymer was then transferred to a scintillation vial capped with a septum and placed
in a sonication bath. The bath was turned on and over the course of 15 minutes the
magnetic nanoparticle solution was injected into the polymer solution. Once injection
was finished, the combined solution was allowed to further sonicate for 15 minutes. The
solution was then removed and put on a shaker table for 72 hours. The chloroform was
then removed via rotary evaporator and further dried under vacuum. Deionized water (DI
H2O) was then added and the vial was sonicated to help mediate suspension into the
water. The water-based particles were then filtered through a 0.2-micron nylon filter to
ensure large aggregates were not present. The solutions were then run through a GPC
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column (Bio-Rad P polyacrylamide beads) to separate excess polymer from the water
dispersible particles.
Click Chemistry [80]: The Cu(I) catalyzed Huisgen 1,3-dipolar cyclo-addition
between the terminal polymer alkyne and the azido-GM3 was done in the aqueous phase
with the azido-GM3 being the limiting reagent. A 2 mol% solution of Cu(II) sulfate
(Sigma Aldrich, 99%) was combined with equivalent molar amounts of the THPTA
(synthesized according to Hong et al.) Cu chelating ligand and let to react for 10 minutes
[81]. This was then transferred into the aqueous alkyne-particle suspension and the azideGM3 was then added. After both additions a 10mol% aqueous solution of (+)-sodium Lascorbate (Sigma Aldrich 98+%) was added to facilitate the reduction of Cu(II) to Cu(I).
The click reactions were left at room temperature for 12 hours, and were then purified
using size exclusion chromatography [78].
Dynamic Light Scattering (DLS) and Zeta Potential Measurements: DLS was
performed on the PEO-coated and GM3-coated magnetic nanoparticles to determine their
hydrodynamic radius. The nanoparticle suspensions were diluted in water and placed into
a cuvette. Three readings were taken at 25°C using Malvern Zetasizer Nano ZS to
determine the intensity average size distribution and z-average diameter. Zeta-potential
measurements of these nanoparticle suspensions were also determined using the same
instrument. The suspensions were diluted with water and added into zeta-cell and three
measurements were taken at 25°C.
Furthermore, 50µg/ml concentration of PEO-MNPs and GM3-MNPs were added
in a cuvette and incubated at 37°C for different time intervals with Dulbecco's modified
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eagle's medium (DMEM) supplemented without/with 10% fetal bovine serum (FBS) to
investigate the stability of MNPs in protein and salt rich biological environment. After
the incubation time, DLS (at 37°C) was performed on the above mentioned
nanoparticles-cell culture suspension to check for any changes in their overall
hydrodynamic diameters.
Fourier Transform Infrared Spectroscopy (FTIR): FTIR microscopy was done
using a Thermo-Nicolet Magna 550 FTIR spectrometer equipped with a Thermo-NicPlan
FTIR microscope. 16 Scans were done for both the sample and the background. Samples
were prepared by dropping a small amount of the water suspended sample on a
germanium plate and left to dry under a heat lamp for 20 minutes. FTIR was done on the
resulting films.
Iron Concentration Determination: 50 µl of magnetite suspension was dissolved
in concentrated HCl, reduced and complexed with 1,10-phenanthroline (Sigma-Aldrich,
99%). UV-VIS was then performed to determine the amount of iron in the known volume
[82, 83].
Culturing of CCD-18Co Cells: CCD-18Co human colon cells (normal) were
procured from American Type Culture Collection (ATCC) and routinely grown on 50
cm2 tissue-culture flask in the presence of Eagle’s Minimum Essential Medium (EMEM)
at 37°C in a humidified atmosphere of 5% CO2 and 95% air. EMEM was supplemented
with 2 mM L-Glutamine, non-essential amino acids, fetal bovine serum (final
concentration - 10%), 100 UI/ml penicillin G, and 100µg/ml streptomycin. Fresh EMEM
complete medium was added to growing cells every 2 days. For determining the

114

biocompatibility of MNPs, cells between passage generation of 12 and 25 were used. All
the media chemicals, 96-well plates and culture flasks required for growing the cells were
obtained from Corning, USA.
Cytotoxicity of MNPs to CCD-18Co Cells [59]: The potential cytotoxicity of both
PEO-MNPs and GM3-MNPs towards CCD-18Co cells was determined by performing
MTS assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega,
USA). For this assay, approximately 1.5 x 104 cells/well (100µl) were seeded (in
triplicates) in transparent flat-bottom 96-well culture-plates at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. After 24 hours, fresh growth medium containing
varying concentrations (10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of
PEO-MNPs and GM3-MNPs was added to the cells and the cells were incubated for
further 24 and 48 hours. After the required incubation time period, cells were washed
twice with sterile tissue-culture grade PBS. 100µl of fresh EMEM culture medium
(without serum) was added to the wells and MTS assay was performed according to
manufacturer’s protocol. Later, the plate was read at 490 nm optical density to measure
the absorbance of the formazan product using a microplate reader (Thermo Scientific
Multiskan™ FC) and percentage cell-viability rate of CCD-18Co cells in presence of
MNPs was determined.
Intracellular Adenosine Triphosphate (ATP) Levels of CCD-18Co Cells in
Presence of MNPs [84, 85]: Intracellular ATP levels of CCD-18Co cells were measured
in presence of both PEO-MNPs and GM3-MNPs to determine if their presence
interrupted/inhibited ATP synthesis in the cells. Approximately 1.5 x 104 cells/well
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(100µl) were seeded (in triplicates) in white flat-bottom 96-well culture-plates at 37°C in
a humidified atmosphere of 5% CO2 and 95% air. After 24 hours, fresh growth medium
containing varying concentrations (10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and
500µg/ml of Fe) of PEO-MNPs and GM3-MNPs was added to the cells and the cells
were incubated for further 24 and 48 hours. After the required incubation time period,
cells were washed twice with sterile tissue-culture grade PBS. 100µl of fresh EMEM
culture medium (without serum) was added to the wells and CellTiter-Glo® 2.0 assay
(Promega, USA) was performed according to manufacturer's protocol with minor
modification in incubation time period. After adding the CellTiter-Glo 2.0 reagent to the
cells, the plate was gently mixed and later incubated at room temperature for 20 minutes.
At the end of this assay, the plate was read in a micro-plate reader with luminescence
capability (Synergy Hybrid H1, Biotek®) and the obtained results were expressed in
relative luminescent units (RLUs).
Cell Membrane Integrity of CCD-18Co cells in Presence of MNPs [24, 86]:
Approximately 1.5 x 104 cells (600µl) were seeded (in duplicates) in 4-well chamber
slide (Corning, USA) at 37°C in a humidified atmosphere of 5% CO2 and 95% air. After
24 hours, fresh growth medium containing maximum concentration of PEO-MNPs and
GM3-MNPs (i.e. 500µg/ml of Fe) were added to the cells and they were further incubated
for 24 and 48 hours. Later, the cells were washed thrice with sterile tissue-culture grade
PBS and finally the cells were re-suspended back in sterile tissue-culture grade PBS.
Now, live/dead® viability assay (Invitrogen, USA) was performed to determine the extent
of cell-membrane damage of CCD-18Co cells in presence of MNPs. Both the staining
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dyes (Ethidium homodimer-1 and Calcein) were mixed together in a sterile
microcentrifuge tube along with sterile tissue-culture grade PBS. The final concentrations
of the dyes were 20µM and 10µM respectively when added to the chamber slides
containing CCD-18Co cells. The chamber slide was then incubated at room temperature
for 40 minutes. The stained cells were then observed under fluorescent microscope with
appropriate fluorescent filter cubes (calcein - excitation/emission: 485/530 nm; ethidium
homodimer-1 - excitation/emission: 530/645 nm) at 100X and 200X magnification. Later,
the images obtained under different fluorescent filters were merged in ImageJ software
(NIH, USA).
Intracellular Glutathione (GSH) Levels of CCD-18Co Cells in Presence of
MNPs [69, 87]: Approximately 1.5 x 104 cells/well (100µl) were seeded (in triplicates) in
white flat-bottom 96-well culture-plates at 37°C in a humidified atmosphere of 5% CO2
and 95% air. After 24 hours, fresh growth medium containing varying concentrations
(10µg/ml, 50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of PEO-MNPs and GM3MNPs was added to the cells and cells were incubated for further 24 and 48 hours. After
the required incubation time period, cells were washed twice with sterile tissue-culture
grade PBS. Intracellular GSH levels were measured by utilizing GSH-Glo™ Glutathione
assay kit (Promega, USA). All the subsequent steps in this experiment were done
according to manufacturer's protocol with a minor modification in incubation times. After
adding the GHS-Glo reagent to the cells, the plate was gently mixed and incubated at
room temperature for 40 minutes. Subsequently, after adding luciferin detection reagent
to the cells, the plate was further incubated for 20 minutes. At the end of this assay, the
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plate was read in a micro-plate reader (Synergy Hybrid H1, Biotek®) and luminescence
intensity of the each well obtained was expressed in relative luminescent units (RLUs).
Intracellular Caspase 3/7 levels of CCD-18Co cells in Presence of MNPs [88,
89]: Approximately 1.5 x 104 cells/well (100µl) were seeded (in triplicates) in white flatbottom 96-well culture-plates at 37°C in a humidified atmosphere of 5% CO2 and 95%
air. After 24 hours, fresh growth medium containing varying concentrations (10µg/ml,
50µg/ml, 100µg/ml, 250µg/ml, and 500µg/ml of Fe) of PEO-MNPs and GM3-MNPs was
added to the cells and cells were incubated for further 24 and 48 hours. After the required
incubation time period, intracellular caspase 3/7 protein levels were determined through
Caspase-Glo® 3/7 assay kit (Promega, USA). The experiment was performed according
to manufacturer's protocol and the plate was incubated for 2.5 hr at room temperature
after adding the Caspase-Glo 3/7 reagent. Later, the plate was read in a micro-plate reader
(Synergy Hybrid H1, Biotek®) and luminescence intensity of the each well obtained was
expressed in relative luminescent units (RLUs).
Statistical Analysis: All the statistical analysis was performed using GraphPad
Prism software (V 7.0, CA, USA). All the experiments were done in triplicates and data
are expressed as Mean±SD. Statistically significant differences between the groups were
evaluated by performing ANOVA. Post hoc group comparisons were calculated through
Tukey's multiple comparisons test. Results showing p-values of ≤0.05, <0.01, and
<0.001 were considered to be statistically significant.
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3. Results and Discussion:
3.1. Synthesis of GM3-MNPs
Magnetite nanoparticles were synthesized using a one-pot thermal decomposition
of iron (III) acetylacetonate and oleic acid [82, 90]. Particles had an average diameter of
23.7 nm with a standard deviation of 1.55 nm (Figure 4.2 A and B). The moment vs. field
(MvH) (Figure 4.3) measurement was done on the particles to confirm the superparamagnetic behavior of the MNPs. Polymer design was based on work by Stone et al.
where a multi-anchored binding approach showed increased stability in comparison to
polymer ligands with a single binding moiety (Figure 4.1) [79].

Figure 4.1 Left: 1) Anionic ring opening of ethylene oxide, 2) alkyne functionalization with propargyl bromide, 3)
deprotection of primary amine, 4) coupling of PEO to PAA, 5) coupling of dopamine hydrochloride to the PEO-PAA.
Right: Click reaction between polymer coated particles and GM3 molecule.
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A

B

Figure 4.2 Magnetite nanoparticles as synthesized before functionalization with PEO-PAA-dopamine polymer. A –
Representative TEM image of the particles. B – Histogram depicting the particle size distribution.

Figure 4.3 Moment vs. Field (MvH) loop showing the superparamagnetic behavior of the magnetite nanoparticles (Msat
~ 53 emu/g Fe).

In this work, however, the chosen catechol was not nitroDOPA but dopamine.
HNMR of the polymer was used to confirm both the structure and molecular weight of
the PEO-PAA-dopamine macromolecule (Figure 4.4).

By using the multi-anchored

approach, the stability in salt and protein buffer solutions is retained even when using
dopamine as the anchoring group [32, 33]. Hydrodynamic diameter and zeta potential of
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the PEO-MNPs before and after click-coupling of GM3 are reported in Table 4.1.

Figure 4.4 HNMR of the final PEO-PAA-dopamine - PAA backbone protons at 1.39 ppm - 1.08 ppm. Alkyne protons
at 4.18 ppm and 2.42 ppm. PEO repeat protons at 3.62 ppm. Dopamine aromatic proton signal partially masked by the
CDCl3 peak, with alkane protons showing up at 2.8 ppm. Reference was tetramethylsilane at ~0 ppm.

Hydrodynamic Diameter
Z Avg. (nm)
def
PEO-MNPs
78.8
GM3-MNPs
88.8

Zeta-potential
(mV)
-8.73
-7.68

Table 4.1 Dynamic light scattering and zeta-potential measurements - Hydrodynamic diameter and zeta potential as
measured by dynamic light scattering before and after GM3 conjugation.

The increase in the hydrodynamic diameter indicates the GM3 glycoconjugate was
successfully coupled to the PEO-MNPs. Attenuated total reflectance Fourier transformed
infrared spectroscopy (ATR-FTIR) also confirmed the GM3 coupling went to completion
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with the disappearance of the azide peak from GM3 at ~2110 cm-1 and the appearance of
a broad alcohol peak in the GM3-MNPs spectrum from 3620-3170 cm-1 (Figure 4.5) [59].

Figure 4.5 FTIR spectra of particles before GM3 conjugation (A), GM3 molecule (B), and after conjugation (C). The
lack of the azide peak in C at 2100 cm-1 indicates purification of unbound GM3 after conjugation was successful.

The presence of biological medium has an important effect on the overall size
diameter and surface charge of the synthesized MNPs. The presence of functional groups
on the surface of MNPs also determines the extent to which it interacts with salts and
proteins. DLS studies were conducted both on PEO-MNPs and GM3-MNPs over a period
of 3 days to evaluate their overall stability in cell-culture medium DMEM in
absence/presence of 10% FBS. As seen from table 4.2, the particle size of PEO-MNPs (in
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water) instantly increased from 78.8 nm to 173.03 nm (more than doubled) within 5
minutes of incubation in presence of DMEM. After 72 hr, the particle size still remained
~170 nm. The presence of FBS in DMEM did not significantly change the overall
diameter of PEO-MNPs during the entire experimental period. However, we did notice a
slight reduction in size of PEO-MNPs in presence of DMEM+FBS. In contrast, GM3MNPs (in water) increased their size from 88.8 nm to 104 nm (an increase of ~18 nm)
when mixed and incubated for 5 minutes in presence of DMEM. Here also the overall
size of GM3-MNPs did not change drastically over 3 days incubation time-period in
presence of DMEM. Interestingly, after mixing GM3-MNPs with media containing
DMEM+FBS for 5 minutes, there was no major change in the diameter (88.8 nm to 91.14
nm). However, after 24 hr and beyond, the size increased to ~110 nm in presence of
DMEM+FBS. Several studies have reported the formation of 'protein-corona' (protein
adsorption) layer on the surface of MNPs when incubated in presence of cell-culture
medium containing high salt and protein concentrations [37, 91, 92]. It is due to this
protein-corona formation that the overall size of the nanoparticles is increased. Moreover,
extended period of protein-corona formation can also affect the colloidal stability of
nanoparticle system in the biological media and eventually the nanoparticles tend to lose
their colloidal stability and form aggregates due to corona formation.
The presence of different types of chemical functional groups found on polymers
and the length of the polymer itself plays an important role as to how and what kind of
proteins interact with the nanoparticle surface and become adsorbed on it [4, 45]. In our
results, we observed a rapid increase in size diameter of PEO-MNPs within 5 minutes of
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incubation with DMEM and once the size was increased, it remained pretty consistent for
the next 72 hr. Such kind of phenomenon can be credited to formation of thick layer of
'hard protein-corona', which essentially represents an irreversible change in the amounts
of proteins, which are getting adsorbed/released over a period of time on the surface of
nanoparticles [93, 94]. Albumin and globulins are most dominant serum proteins found in
any cell-culture medium [4]. Major ionic salts that are present in any cell-culture medium
include sodium (Na+), potassium (K+), chloride (Cl-), and bicarbonate (HCO3-). The PEOPAA polymer that we used as multi-anchored stabilizing agent for PEO-MNPs have a lot
of reactive alkyne groups on its surface that are free and can potentially interact with the
above mentioned serum proteins and ionic salts present in DMEM. A study done by
Ekkebus et al. showed that terminal alkyne groups could selectively react with cysteine
amino acid via thiol-alkyne side chain reaction [95]. The size increase of PEO-MNPs
when mixed with DMEM could be due to the chemical interactions taking place between
the free alkyne groups present on our polymer chains with thiol end-group containing
amino acids like cysteine and cystine. Moreover, several coenzymes and cofactors
present in DMEM contain thiol groups, which can also interact with alkyne. The abovementioned chemical reactions taking place between alkyne and thiol-rich compounds
might be one of the reasons for formation of protein-corona around PEO-MNPs in
DMEM and thereby increasing its overall diameter size by more than 2-fold. In the case
of GM3-MNPs, the PEO-PAA polymer with alkyne group underwent 'click reaction' to
covalently attach GM3 molecule through alkyne-azide linkage. So, GM3-MNPs would
have relatively less amount of free alkyne groups, which can interact with serum proteins
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and ionic salts of DMEM and hence less amount of proteins would get adsorbed on its
surface and forms a thin layer of protein-corona which would eventually increase the
overall size of GM3-MNPs but only to a certain extent (increase of

~18 nm).

Furthermore, it is worthwhile to note that presence of multi-anchored DOPA group is
also responsible for maintaining colloidal stability of MNPs in biological environment
via intact stearic interactions. Recent work of Stone et al. (2015) suggested that multianchored dopamine groups present on MNPs made them colloidically stable in FBS
medium compared to mono-anchored groups that lost their stability by forming large
aggregates having size diameter of >500 nm [34].
Hydrodynamic Diameter Z. average (nm) of MNPs in Presence of Cell-Culture
Medium for Different Time-Intervals
PEO-MNPs
(in H2O)

PEO-MNPs
+ DMEM

PEO-MNPs
+ DMEM +
10% FBS

GM3-MNPs
(in H2O)

GM3-MNPs
+ DMEM

GM3-MNPs
+ DMEM +
10% FBS

t = 5 min

78.8 nm

173.03 nm

167.03 nm

88.8 nm

104.00 nm

91.14 nm

t = 24 hr

78.4 nm

171.97 nm

164.70 nm

88.6 nm

106.00 nm

106.00 nm

t = 48 hr

78.1 nm

171.17 nm

165.83 nm

88.1 nm

106.80 nm

109.90 nm

t = 72 hr

78.1 nm

172.50 nm

164.77 nm

88.3 nm

108.00 nm

110.30 nm

Table 4.2 Dynamic light scattering measurements - Hydrodynamic diameter of MNPs as measured by dynamic light
scattering in presence of cell-culture medium DMEM.

The presence of nanomaterials in cell-lines is one of the many factors responsible
for inducing toxicity in them. Different nanoparticles, when presented with direct contact
to cells, can elicit cytotoxic responses inside mitochondria. One of the many in vitro
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assays, which determine the damage done to mitochondria in presence of nanoparticles, is
to quantify and measure the reductase/dehydrogenase enzymes activity inside the living
mitochondria [39, 96]. MTS assay in one of the frequently employed cytotoxicity assay,
which measures the amount of tetrazolium salt that is bio-reduced to formazan product by
viable cells. This amount can then be detected colorimeterically and formazan produced
is directly proportional to the number of living cells. The cytotoxicity of PEO-MNPs and
GM3-MNPs to CCD-18Co cells was measured by CellTiter 96® Aqueous One Solution
Cell Proliferation Assay [59]. Increasing concentrations of both MNPs were added and
the cells were incubated for 24 and 48 hr. As seen from figure 4.6 A, PEO-MNPs were
found to be highly cytotoxic to CCD-18Co cells above 100µg/ml concentration after 24
hr of exposure in a dose-dependent manner. <5% cell-viability was observed in the cells
exposed to 500µg/ml concentration of PEO-MNPs at the end of 24 hr. Interestingly;
GM3-MNPs did not show any significant cytotoxicity at all concentrations. In
comparison to 24 hr time-period, PEO-MNPs showed significant cytotoxicity to the cells
after 48 hr exposure even at 100µg/ml concentration (Figure 4.6 B). Above this
concentration, <5% cell-viability of CCD-18Co cells was seen. To our surprise, cells
exposed to GM3-MNPs for 48 hr did not show any significant cytotoxicity. Even the
maximum concentration of 500µg/ml of GM3-MNPs showed >90% viability rate. PEO
polymer attached to nanoparticle surface is generally found to be biocompatible both in
in vitro and in vivo settings [25, 26, 28]. However, there have been few reports of toxicity
of PEO coated nanoparticles. In a recent study conducted by Escamilla-Rivera et al.,
MNPs coated with PEG were found to have 50% cell-viability at 100µg/ml concentration
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after 48 hr exposure to THP-1 macrophages [97]. Also, the presence of PAA group on the
polymer has been described to have significant toxicity in animal models [71, 98, 99]. It
should be also noted that cell-viability rate also depends on the length of PEO tails
present on the surface of MNPs as reported by Hafeli et al. [100]. Their study showed
that by increasing tail length of PEO polymer (from 0.75 kDa to 15 kDa), cell-viability
rate

of

various

human

cell-lines

also

increased.

Also,

the

presence

of

carbohydrate/glycoconjugate molecules on MNPs have been reported to have no
significant cytotoxicity to different cell-lines the results of which were similar to what we
observed [101-103].

Figure 4.6 Cell-viability cytotoxicity MTS assay: a) CCD-18Co cells exposed to varying concentrations of PEO-MNPs
for 24 hr; b) CCD-18Co cells exposed to varying concentrations of GM3-MNPs for 48 hr. Data is expressed as Mean ±
SD (n=3); Statistical analysis – Analysis of Variance (ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value
<0.001
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The amount of ATP level present in any cell determines its metabolic state. In the
presence of any toxic materials/chemicals, the metabolic state of the cell will change and
the intracellular ATP levels can drop if there is any significant cytotoxicity to the cells.
Higher levels of intracellular ATP commonly indicates that the cell is metabolically
active and their level directly correlate to the actual number of living cells. Numerous
research studies have reported a significant decrease in intracellular ATP levels of cells in
presence of different types of nanoparticles [104-106]. To further understand the inherent
cytotoxic mechanisms of MNPs on the inner cell membrane biochemical cycles taking
place inside mitochondria, we measured the intracellular ATP levels of CCD-18Co cells
based on luminescent assay. The cells were incubated with different concentrations of
PEO-MNPs and GM3-MNPs for 24 and 48 hr. As seen from figure 4.7 A and B, the ATP
levels of the cells started to decrease substantially when exposed to PEO-MNPs above
100µg/ml concentration. More than 90% reduction in the ATP levels was observed for
250µg/ml and 500µg/ml concentrations of PEO-MNPs. In comparison, cells exposed to
GM3-MNPs for 24 hr did not show any significant decrease in ATP levels at all
concentrations. When the exposure time was increased to 48 hr, cells in presence of PEOMNPs showed a rapid decline in intracellular ATP levels beginning from 100µg/ml
concentration (Figure 4.7 B). At concentrations above 100µg/ml, a significant reduction
(>95%) in ATP levels was seen in presence of PEO-MNPs. Several reports have
suggested that the kind of polymer coating and size of MNPs could play an important
role in maintaining ATP levels inside the cells. In one such study, MNPs coated with
different polymers like DEAE, chitosan and PEI exhibited variation in its cytotoxic
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response to human brain microvascular endothelial cell-line with PEI-MNPs showing
maximum cytotoxicity [107]. In another study, MNPs functionalized with starch were
incubated with murine macrophage cell-line for 48 hr and the authors observed a drastic
decrease in ATP levels of the cells [108]. However, presence of GM3-MNPs to the CCD18Co cells did show a slight decrease (not significant) in ATP levels at concentrations
above 250µg/ml, thereby, proving that GM3-MNPs do not cause any detrimental toxic
effects on the overall functioning of ATP synthesis mechanisms inside mitochondria in
CCD-1Co cells. These results prove that PEO-MNPs can possibly interfere with the ATP
synthesis pathways inside the mitochondrial membrane, which can cause reduction in
proton motive force and membrane depolarization.

Figure 4.7 Intracellular ATP levels of CCD-18Co cells in the presence of MNPs using CellTiter Glo 2.0 assay. A) ATP
levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) ATP levels of cells exposed to GM3MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical analysis – Analysis of
Variance (ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001
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Next, we evaluated the potential toxicity of MNPs to CCD-18Co cells by
performing membrane integrity assay. It is one of the commonly employed in vitro assays
that determine the extent of membrane damage of mammalian cells when exposed to
various nanomaterials [75, 96]. Most of these assays utilize a mixture of fluorescent dyes
that can interact with specific enzymes present inside the cells depending on their ability
to enter the cell. In our study, we exposed the cells only to highest concentration of
MNPs (500µg/ml) based on the preliminary cytotoxicity results that we observed. After
the predetermined incubation time-period, live/dead viability assay was done in presence
of 2 different fluorescent dyes, calcein AM and ethidium homodimer-1. Calcein AM is a
cell-permeable dye, which is non-fluorescent to begin with. Once inside the living cell,
various intracellular esterases break down this dye and it is retained inside the cells that
have intact membrane and can now emit intensely green fluorescence. Contrary, ethidium
homodimer-1 dye cannot enter the live cell that has intact membrane. Those cells whose
cell-membrane integrity has been compromised only take it up and once inside these
damaged cells, it can brightly emit red fluorescence. As seen from figure 4.8 C, CCD18Co cells exposed to PEO-MNPs after 24 hr showed a distinct change in their
morphology and structure compared to control cells, which showed perfect slender and
elongated fibrils (Figure 4.8 A). The cells were found to be clumped together in small
irregular round/oval shapes. There was partial membrane damage to the cells as evident
from limited red fluorescence. After 48 hr exposure, majority of the cells exposed to
PEO-MNPs suffered extensive membrane damage (as seen by intense red fluorescence)
and the cells also shrunk in size (Figure 4.8 D). We also observed extensive cell-
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detachment in CCD-18Co cells in presence of PEO-MNPs. Such cell features are
indicative of necrosis/ apoptosis. In comparison, cells incubated with 500 µg/ml of GM3MNPs for 24 and 48 hr did not show any visible cell-membrane damage (Figure 4.8 E
and F). More than 90% viability has seen in these cells. However, we did notice a small
change in the overall size and arrangement of the cells. Compared to control group, cells
exposed to GM3-MNPs had smaller fibrils. Also, their overall size dimensions (in terms
of length and width) slightly reduced. They were also found to be growing at further
distance from each other and there was hardly any overlapping of cell fibrils with each
other referred to cell retraction. One possible explanation for such morphological change
in cells in presence of MNPs might have to do with maintaining of cytoskeleton
structures that includes actin and tubulin filaments. Both these structures are essential for
proper growth and maintenance of cells as they directly take part in cell-cell
communication, transport of nutrients and other vital organelles. Nonetheless, the change
in cell morphology in presence of MNPs is something that has been already investigated
previously. Few research studies have reported that MNPs functionalized with dextran,
citric acid and PEG can effectively disrupt the overall cytoskeleton arrangement in
different cell-lines through destruction of actin and microtubules through cell uptake [86,
109, 110]. Also, at high concentrations of MNPs (500 µg/ml and 1000 µg/ml), the overall
length and diameter of murine neural progenitor cells and primary human blood
outgrowth endothelial cells were found to be condensed and these cells also showed
retraction properties (growing but tend to repeal from each other) during their growth
cycle which is similar to what we observed in CCD-18Co cells exposed to GM3-MNPs
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[111]. It also reduced the expression of focal adhesion kinase (FAK) protein, which is
suggested to have damaging repercussions on kinase signaling pathways that maintains
the cytoskeleton structures. Such disruptions in cytoskeleton pathways can activate proapoptosis signaling pathways in the cells, which can lead to cell-death. Thus, the results
of our live/dead staining assay suggests that PEO-MNPs can possibly interfere and
destroy cell cytoskeleton structures that can stall the regular cell cycle and cause celldeath. Whereas, the presence of GM3 molecule on MNPs can potentially prevent such
drastic cytoskeleton toxicity of CCD-18Co cells.

24 hr

48 hr

Control

PEOMNPs

132

GM3MNPs

Figure 4.8 Live/Dead staining assay using calcein AM and ethidium homodimer-1 dyes. CCD-18Co cells were
incubated in presence of PEO-MNPs and GM3-MNPs for 24 and 48 hr (Concentration - 500µg/ml). Live cells appear
green in color and dead cells appear red in color. All the images were merged together for both green and red channel
filters of the microscope. A, B - control cells (no MNPs); C, D - cells exposed to PEO-MNPs; E, F - cells exposed to
GM3-MNPs. Magnification: 100X; Scale bar - 100µm.

It is known that the amount of reactive oxygen species in the cellular environment
gives an indication of the oxidative stress levels. Glutathione (GSH) is an important and
powerful antioxidant present in the mammalian cell. It normally exists in oxidized dimer
form (GSSH). However, when the cell is experiencing oxidative stress due to presence of
reactive oxygen species, free radicals, and toxic metal ions, GSSH is converted into its
reduced monomeric form, GSH, which is an indicator of cellular oxidative stress that can
lead to cell death or apoptosis [112, 113]. There have been numerous reports of increased
oxidative stress in cells exposed/treated with different kinds of nanomaterials especially
MNPs [114-116]. So, in order to evaluate whether CCD-18Co cells are undergoing
cellular oxidative stress in presence of MNPs, we carried out GSH-glo assay to check for
any changes in the overall GSH levels. At the end of 24 hr exposure to PEO-MNPs, the
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GSH levels in the cells decreased drastically at concentrations of 250µg/ml and 500µg/ml
(Figure 4.9 A). In the case of GM3-MNPs, cells lowered their overall GSH counts only at
highest concentration of 500µg/ml. Compared to 24 hr, cells exposed to 48 hr of PEOMNPs and GM3-MNPs exhibited concentration-dependent decrease in GSH levels
starting from 50µg/ml concentration (Figure 4.9 B). Interestingly, even the lowest
concentration of 10µg/ml was sufficient enough to cause a substantial decline in cellular
GSH levels. The overall reduction in GSH levels obtained in this experiment was not
something unexpected. Numerous works have examined the effect of MNPs in disturbing
the overall mechanisms of antioxidant pathways in cells [117-119]. The most common in
vitro and in vivo toxicity of MNPs develop due to production of reactive oxygen species
(ROS), which include singlet oxygen, hydrogen peroxide, hydroxyl radicals and
superoxide anions [114, 120]. MNPs are likely to be taken up by the cells via different
endocytic pathways depending on their size and surface chemistry [121]. Once inside the
cells, MNPs are typically degraded in the lysosomes into ferrous (Fe2+) ions due to their
low pH environment. These Fe2+ ions could potentially enter the mitochondrial
membrane system through membrane depolarization and interact with different enzymes
of the electron transport system especially with NADPH oxidase, oxygen and hydrogen
peroxide producing ferric ions (Fe3+) and highly reactive hydroxyl radicals through
Fenton chemistry [38, 122]. High levels of ROS species can deteriorate the cellular levels
of GSH thereby causing oxidative stress. A study conducted by Watanabe et al. reported
that exposing MNPs to human alveolar epithelial cells caused DNA damage, increased
ROS production and reduced GSH levels even at low concentration of 10µg/ml, which is
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similar to what we observed [123]. Similarly, significant increase in ROS levels and
simultaneous reduction in GSH levels was observed in human breast cancer cells when
exposed to MNPs. Here too, the authors described these effects to be time and
concentration-dependent [124]. Based on these results, we can aptly deduce that both
type of MNPs systems used in our experiments are responsible for generating increased
ROS levels along with reducing intracellular GSH levels in CCD-18Co cells. Further
studies needs to be conducted to decide the exact levels of several intracellular ROS (e.g.,
hydroxyl ions, hydrogen peroxide, singlet oxygen etc.) that are getting boosted due to
presence of MNPs to fully elucidate the role of ROS in causing cellular toxicity in
presence of MNPs.

Figure 4.9 Intracellular Glutathione (GSH) levels of CCD-18Co cells in the presence of MNPs using GSH-Glo assay.
A) GSH levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) GSH levels of cells exposed to
GM3-MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical analysis –
Analysis of Variance (ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001
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The presence of nanomaterials in biological system has been shown to induce
apoptosis in cells by activating various cell-death signaling pathways [43, 125]. In order
to determine whether CCD18-Co cells are showing any apoptotic activity in presence of
MNPs, we quantitatively measured the levels of caspase3 and caspase7 proteins. These
caspase proteins belong to cysteine-aspartic acid protease (caspase) family. This family
also includes other caspase proteins like caspase6, caspase8, caspase9, and caspase10 that
play a central role in activation of cell apoptosis [126, 127]. Upon detecting a major
change in the normal biochemical processes occurring inside the mitochondria, different
signaling pathways are activated, which can trigger the activation of caspase family
proteins. One of the last proteins of caspase family to get activated before the cell
inadvertently goes into cell-death stage is caspase3 [128]. So, we performed caspase-glo
3/7 assay on CCD18-Co cells exposed to MNPs to check if their presence has activated
the caspase signaling pathways leading to apoptosis. On incubating the cells with PEOMNPs, we did not see any significant change in the levels of caspase3/7 proteins up to
250µg/ml concentrations (Figure 4.10 A). However, cells exposed to 500µg/ml PEOMNPs showed a substantial increase in activity of caspase3/7 proteins, which suggests
that the cells might be undergoing apoptosis. In comparison, cells incubated with GM3MNPs for 24 hr maintained similar caspase3/7 levels at all concentrations. When the
exposure time of MNPs to cells was increased to 48 hr, cells incubated with both
250µg/ml and 500µg/ml concentrations of PEO-MNPs showed a notable rise in
caspase3/7 levels (Figure 4.10 B). This proves that even at concentration of 250µg/ml of
PEO-MNPs, the cells may be experiencing apoptosis. Surprisingly, when were incubated
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with GM3-MNPs for 48 hr, we did not observe a significant change in the caspase levels
until the concentration was 500µg/ml. These results suggests that both PEO-MNPs and
GM3-MNPs are able to activate caspase signaling events in CCD-18CO cells only when
presented with highest concentrations of MNPs. However, it seems that the exposure time
does play a critical role in induction of apoptosis as the overall caspase levels were
elevated at 48 hr compared to 24 hr. Similar kind of results were obtained in several
research findings that showed time-dependent increase in caspase protein levels in
presence of MNPs [89]. The results obtained in this experiment are a little different (in
terms of concentration-dependent rise in caspase levels) than what has been reported
earlier. In one of the study done by Yin et al, the caspase3 levels in rat cerebellum cells
showed a dose-dependent increasing trend when exposed to silver nanoparticles [129]. In
another study, the size and surface functionalization of polystyrene latex nanoparticles
played a significant part in initiating caspase dependent apoptotic pathways in human
alveolar epithelial cells [130]. They noticed that cells exposed to 100 nm amine-coated
nanoparticles had significantly higher levels of caspase proteins compared to those
exposed to 50 nm size nanoparticles and also to carboxyl-coated nanoparticles. Hence,
based on our results of caspase3/7 assay, it seems that the surface chemistry and exposure
time are important parameters to consider when using MNPs for therapeutic applications.
The levels of other apoptotic proteins needs to be determined in order to completely
understand the if cellular toxicity mechanism in presence of MNPs is indeed due to
activation of apoptosis signaling pathways.
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Figure 4.10 Intracellular caspase3/7 activity levels in CCD-18Co cells exposed to MNPs using Caspase-Glo 3/7 assay.
A) Caspase3/7 levels of cells exposed to PEO-MNPs at increasing concentrations for 24 hr; B) Caspase3/7 levels of
cells exposed to GM3-MNPs at increasing concentrations for 48 hr. Data is expressed as Mean ± SD (n=3); Statistical
analysis – Analysis of Variance (ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001

Special Discussion: In this study, we have investigated and compared
biocompatibility of PEO-MNPs with GM3-MNPs in normal human colon cell-line CCD18Co. The main difference in terms of chemical functionality between PEO-MNPs and
GM3-MNPs was the presence of glycoconjugate molecule GM3 on the surface of GM3MNPs. As mentioned earlier, the type of surface functional groups present on MNPs
plays an important role in regulating overall biocompatibility of the nanoparticle system
both in in vitro and in vivo settings. Other factors that also play their part in imparting
nanoparticle biocompatibility include surface charge, size, kind of polymer used, the
extent to which it can form protein-corona in cell-culture medium, concentration of
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nanoparticles, type of cells interacting with nanoparticles etc. [92, 94]. In order to check
if MNPs were able to form protein-corona in protein and salt-rich biological medium,
DLS studies were performed and it showed that PEO-MNPs significantly increased their
overall size diameter. This increase can be attributed to formation of thick layer of
protein-corona on the surface of nanoparticles. More specifically, the free alkyne group
present on our heterobifunctional PEO polymer can potentially interact with various
thiolated amino acids present in the cell-culture medium DMEM and due to this different
protein molecules can bind to the surface of PEO-MNPs forming the corona and thereby
increasing the size and possibly even altering the charge of nanoparticles [94, 95]. In
contrast, there was only marginal diameter increase (~18 nm) for GM3-MNPs when
mixed with DMEM. These results suggest that carbohydrate glycoconjugate coated
MNPs can possibly act as drug-delivery agents as they do not significantly interact with
the serum proteins, which would help in retaining its original physico-chemical
properties. However, further detailed studies involving spectroscopic techniques needs to
be done in order to fully identify the proteins interacting with MNPs and understand these
mechanisms as the formation of protein-corona can potentially determine the nanoparticle
uptake into the cells that would ultimately regulate cellular processes (Figure 4.11).
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Figure 4.11 Formation of protein-corona on the surface of nanoparticles a) Formation of protein-corona on the
nanoparticle surface depending on the physico-chemical properties of the initial material and b) Impact of protein-
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corona on structural and functional properties of protein molecules interacting with biological medium. Reprinted from
[11] - Reproduced with permission from Nature Publishing Group.

Over the last decade, numerous studies have expressed grave concern regarding
the biocompatibility of engineered nanoparticles that are being extensively used for
biomedical applications (e.g., gold nanoparticles, silver nanoparticles, magnetic
nanoparticles etc.). These nanoparticles have been found to significantly affect the
molecular machinery of the cells at different levels. Since nanoparticles have large
surface area, even a minute change in their physico-chemical properties can have drastic
effect on the way it interacts with cells. Among different factors responsible for these
changes, the chemical properties and presence of surface chemical groups tend to
outweigh all the other factors. The kind of chemical groups can potentially dictate if the
nanoparticles have the ability to alter the electron accepting/donating mechanisms
occurring inside the cells. Currently, the best possible explanatory model in determining
the toxicological effects of engineered nanoparticles relies heavily on the generation of
ROS [114, 120]. Among different type of nanoparticles, MNPs have been known to
produce ROS when exposed to mammalian cells [114-116]. It is this very property that
has made MNPs to be used for targeted drug delivery for cancer therapy in clinical use.
MNPs are able to enter the cells via endocytosis and once inside, they can freely interact
with lysosomes or endosomes and in this process they can increase ROS levels via
Fenton reaction in the cells putting them under increased oxidative stress environment
[114, 122]. In normal metabolic state, the ROS levels are usually found to be low in the
cells. To counteract them, different antioxidant enzymes (catalase, superoxide dismutase,
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etc.) and glutathione are produced by the cells. However, when ROS levels are increased
significantly, the GSH levels and antioxidant enzyme levels are reduced and the cell
experiences increased oxidative stress. In our experiments too, both PEO-MNPs and
GM3-MNPs decreased intracellular GSH levels of CCD-18Co cell indicative of increased
oxidative stress. Depending on the amount of oxidative stress, different response
elements in the cells are activated. For example, at low level of oxidative stress,
transcription factor Nrf-2 gets activated which in turn increases the production of various
antioxidant enzymes which would typically restore the redox balance in the cells [120].
However, when the cells are experiencing high level of oxidative stress, numerous cellsignaling pathways related to inflammation and cytotoxicity are activated (e.g., mitogenactivated protein kinase (MAPK), nuclear factor κB (NF-κB), AP-1). Higher ROS levels
also interfere with the electron transport system (ETS) of mitochondria that could
potentially reduce the activity of ATP synthase pump leading to membrane
depolarization and lipid peroxidation, which can induce irreversible damage of plasma
membrane. These pathways can also activate pro-apoptosis factors in the cells, which
would eventually result in activation of caspase molecules leading to apoptosis (Figure
4.12). Thus, in order to get an overall view of the ROS induced toxicity of our MNPs,
elaborate studies on cellular uptake of MNPs, gene expression changes taking place in
mitochondria (those involved in ETS chain), and extensive analysis of inflammatory
factors involved in these mechanisms are warranted in in vitro conditions before these
MNPs can be used for toxicity testing in animal models. Moreover, as MNPs are clinical
used in magnetically triggered drug delivery through alternate magnetic fields, complete
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toxicity profile of these MNPs should be evaluated by exposing the cells to magnetic
fields.

Figure 4.12 Possible mechanisms of nanoparticle toxicity induced by increased ROS levels. Reprinted from [131] Reproduced with permission from Elsevier Ltd.

4. Conclusion:
We successfully synthesized multi-anchored glycoconjugate functionalized GM3MNPs based on 'click-chemistry' platform that are stabilized with heterobifunctional
PEO-PAA polymer having dopamine molecules as robust anchoring agents to the ironoxide core. The above-mentioned GM3-MNPs were fully characterized through
numerous techniques and their stability in cell-culture medium DMEM was investigated.
In the presence of high salt and high protein environment of DMEM, MNPs were able to
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form protein-corona layer on their surface within rapid time duration. Size diameter of
PEO-MNPs increased significantly compared to GM3-MNPs suggesting formation of
thick protein-corona layer. PEO-MNPs are able to cause strong decrease in cell-viability
of CCD-18Co cells at concentrations above 100 µg/ml whereas GM3-MNPs did not show
any cytotoxic effects on the cells. Also, intracellular ATP levels of CCD-18Co were
significantly diminished in presence of PEO-MNPs but not GM3-MNPs indicative of
interference in the activity of ATP synthase pump. PEO-MNPs also compromised the
membrane integrity of the cells possibly due to apoptosis/necrosis; however, cells
exposed to GM3-MNPs showed significantly different cell morphology but no membrane
damage which indicates subtle changes in cytoskeleton arrangement of the cells. Also,
presence of PEO-MNPs and GM3-MNPs to the cells resulted in substantial decrease in
the intracellular GSH levels in a time and concentration-dependent manner that clearly
denotes existence of increased oxidative stress via formation of reactive oxygen species.
Finally, we also determined if MNPs were able to induce apoptosis in normal colon cells
by means of measuring the activity of caspase proteins. The levels of caspase3 and
caspase7 proteins were found to be remarkably elevated in the cells in presence of PEOMNPs at higher concentrations, which was dependent on exposure time. Thus, based on
the results that we obtained, it can be appropriate to assume that reduction of GSH due to
increase in ROS levels and increased production of caspase3/7 proteins leading to
apoptosis are few of the prominent factors responsible for triggering cellular toxicity in
CCD-18Co cells in presence of PEO-MNPs. Some of the important nanoparticle
synthesis parameters that directly affect toxic potential of MNPs and which warrants
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further in-depth studies include controlling the amount of PEO-PAA polymer groups that
are being grafted onto the surface of MNPs as excessive free groups can interact with
protein molecules altering the physico-chemical properties of MNPs, effect of postsynthesis purification steps once the polymer is attached to the core of nanoparticle as
chemical residues can also contribute to overall toxicity of MNPs. It is also important to
mention here that since presence of glycoconjugate molecules on MNPs renders them
relatively biocompatible, efforts should be made to increase the general efficiency of
'click chemistry' reactions so that more glycoconjugate molecules are being attached to
PEO-PAA polymer. Furthermore, investigation of immunotoxicity of MNPs is necessary
as colon cells can trigger inflammatory response signaling pathways (e.g., nuclear factor
κB (NF-κB), mitogen-activated protein kinase (MAPK)) in presence of MNPs, which can
also lead to apoptosis. As we observed reduction in GSH levels of colon cells in presence
of MNPs implying increased ROS generation, gene expression studies of ROS gene
cluster would be valuable to explain the exact underlying mechanisms of increased
oxidative stress that could also lead to apoptosis. Also, by attaching proper antioxidant
chemicals/drugs to GM3-MNPs, they can be effectively used for targeted drug-delivery
to colon cells remotely via magnetothermal drug release mechanisms in presence of
alternate magnetic fields for therapeutic applications in treating infections caused during
post-IBS.
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Chapter 5
Concluding Remarks
Functionalized MNPs are currently one of the most commonly used nanomaterials in
biomedical settings. Among different functional groups, MNPs having carbohydrate
molecules attached to them have shown excellent biocompatibility in both in vitro and in
vivo conditions. This dissertation work mainly focuses on developing proof-of-concept
MNPs functionalized with specific sialic-acid based carbohydrate glycoconjugate
molecule

(Neu5Ac(α2-3)Gal(β1-4)-Glcβ-sp)

(GM3-MNPs)

and

evaluating

their

interaction with enterotoxigenic E. coli strain EC K99. These functionalized MNPs were
synthesized by using special heterobifunctional PEO polymer comprising of dopamine
molecules on one end and free alkyne groups on other end on which the GM3 molecule is
attached via 'click chemistry' linkage. Specific interactions occurred between EC K99 and
GM3-MNPs, which resulted in formation of aggregates of bacteria-nanoparticle complex
as described in chapter 2. These results show that it is possible to create bacteria-specific
multifunctional MNPs based on carbohydrate molecules that can find useful applications
in rapid detection (ID system) of pathogens in biological samples.
Later, in chapter 3, we evaluated the practicability of using GM3-MNPs developed on
multi-anchored PEO-PAA dopamine platform for targeted killing of EC K99 in presence
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of AMF. High degree of clinically significant specific in vitro bacterial killing (in both
pure culture and mixed culture environment) was seen in EC K99 in presence of AMF
possibly due to MagMED phenomenon and destruction of bacterial cell membrane. These
results are pivotal since bacterial infections occurring in GI tract has heterogeneous
environment i.e. presence of beneficial gut bacteria and using antibiotics for treating such
infections would give rise to potential drug-resistant bacteria along with destroying the
beneficial micro-flora. Future studies are warranted to test the effectiveness of AMF
treatment

in

multi-drug

resistant

bacteria

e.g.,

MRSA,

carbapenem-resistant

enterobacteriaceae group. Several important parameters like core-size of MNPs, polymer
length, concentration of MNPs, magnetic field strength and applied frequency of AMF
should be fine-tuned to improve the efficacy of treatment regimen in both in vitro and in
vivo conditions. Once these factors are established, MNPs and AMF together would act
as novel non-antibiotic agents for treating clinically relevant bacterial infections, thereby,
eliminating the need of using antibiotics and diminishing the rise of drug-resistant
bacteria.
Different strategies have been employed to impart colloidal stability to MNPs in
biological environment. The type of polymer used in stabilizing MNPs plays an
important role in this regard. The presence of chemical functional group on surface of
MNPs would define how it interacts with serum proteins and mammalian cell in in vitro
setting, which would then determine its biocompatibility. Thus, finally in chapter 4,
biocompatibility studies were undertaken to figure out the toxicity profile of MNPs
developed on multi-anchored PEO-PAA dopamine platform. GM3-MNPs were able to
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maintain their overall colloidal stability in protein-rich environment as they formed
limited 'protein-corona'. They were also found to be fairly biocompatible (other than
reducing GSH levels) compared to PEO-MNPs when exposed to normal colon cells
CCD-18Co. This shows that presence of carbohydrate groups on MNPs surface can
potentially impart biocompatibility. Nonetheless, extensive toxicity studies in animal
models are necessitated for these carbohydrates functionalized MNPs. By carefully
controlling different parameters of MNPs synthesis like size of MNPs, post-synthesis
purification techniques, and efficient ligand-exchange reactions, it is possible to create
MNPs functionalized with carbohydrate groups that are fully biocompatible and can be
used in therapeutic applications.
The results obtained in this work suggest that carbohydrate glycoconjugate functionalized
MNPs have great potential to be effectively used in clinical settings as multifunctional
theragnostics agents for e.g., simultaneous detection, isolation & destruction of targeted
pathogens, targeted drug-delivery & imaging and as effective vaccine candidates.
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paper(s) specified below in the printed and microfilm version of your thesis. You may
also make available the PDF version of your paper(s) that the RSC sent to the
corresponding author(s) of your paper(s) upon publication of the paper(s) in the following
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